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Abstract 
Cancer cells depend heavily on sustained expression of anti-apoptotic proteins. 
Targeting transcription to suppress these anti-apoptotic proteins seems a 
promising strategy for anti-cancer therapy. Cyelin-dependant kinase 9 (CDK9) 
regulates transcription elongation by phosphorylating Ser2 on the C-terminal 
domain of RNA polymerase II, while CDK 7 phosphorylates Ser5 during 
transcription initiation. A screening cascade comprised of an MTT assay, a 
caspase-3 activation assay, a p53 stabilization assay and a mitotic index assay 
was developed to classify compounds and identify lead transcriptional CDK 
inhibitors from a novel class of 2,4,5-trisubstituted pyrimidines. Compounds 
S3-41 and CDKI-71 are the most potent CDK9 inhibitors identified by the 
screening cascade. They showed potent anti-proliferative activity in the MIT 
assay and induce both caspase-3 activity and p53 protein level at the 0150 
concentration. In addition, no significant effect on mitotic index was observed. 
The detailed mechanism of action of CDKI-71 was further investigated and 
compared with the clinical compound, flavopiridol. Like flavopiridol, CDKI-
71 displayed potent cytotoxicity and caspase-dependent apoptosis that were 
closely associated with the inhibition of RNAPII phosphorylation at Ser2. This 
indicated effective targeting of cyclinT -CDK9 and the downstream inhibition 
of anti-apoptotic proteins such as Mcl-l in cells. Similar to flavopiridol, CDKI-
71 down-regulated a large range of genes, including Mcl-l and Bcl-2. No 
correlation between apoptosis and inhibition of cell cycle CDKs 1 and 2 was 
observed. Non-transformed lung fibroblast cell lines showed resistance to 
VII 
CDKI-71 treatment. In contrast, flavopiridol showed little selectivity between 
cancer and nonnal cells. Flavopiridol also induced genotoxic stress through the 
induction of DNA double-strand breakage. These results suggest that CDKI-71 
has a great potential to be developed as an anti-cancer agent. 
Another study focused on in vitro anti-tumour mechanism of CDKI-83, a dual 
inhibitor of CDK9 and CDKI, was perfonned in A2780 ovarian cancer cells. 
CDKI-71 presented potent anti-proliferation activity and induced apoptosis in 
A2780 cells. By inhibiting cellular CDKI and CDK9 activities, CDKI-83 
arrested cells in 02 phase and reduced anti-apoptotic proteins at both mRNA 
and protein levels, respectively. This study suggests that the combination of 
CDK9 and CDKI inhibition results in effective induction of apoptosis in 
cancer cells. 
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Chapter One: Introduction 
1.1 Cancer 
Cancer is a class of diseases characterized by uncontrolled cell growth of 
abnormal cells which invade and destroy other tissues. Every year, more than 
1.3 million people in the US and UK are diagnosed with cancer, leading to 
165,000 deaths per year (David and Zimmerman, 2010). According to an 
official report (Babb, 2000), cancer has become the major cause of death in 
England and Wales. 
Remarkable progress has been seen in cancer research and treatment in the past 
three decades. However, cancer continues to be a worldwide killer. The causes 
of cancer can be divided into two groups: those with internal factors (such as 
inherited mutations, hormones, and immune conditions) and those with 
environmental factors (such as diet, tobacco, infractions). Although dynamic 
changes are involved in cancer and all cancers are due to multiple mutations 
(Hahn and Weinberg, 2002; Loeb and Loeb, 2000), most mutations are a result 
of interaction with the environment and only 5-10 % of all cancers are due to 
an inherited gene defect (Anand et aI., 2008; Lichtenstein et aI., 2000). 
1.1.1 Hallmarks of cancer 
Douglas Hanahan and Robert A. Weinberg have proposed six hallmarks of 
cancer which are shared in common by most, if not all, types of human 
tumours (Hanahan and Weinberg, 2000): sustaining proliferative signalling, 
evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis and metastasis (Figure 1.1). These 
capabilities provide a solid foundation for understanding the biology of cancer 
and are described in turn below. 
Figure 1.1 The six hallmarks of cancer (Hanahan and Weinberg, 2011). 
1.1.1.1 Sustaining proliferative signalling 
Before moving from a quiescent state into a cell growth-and-division cycle, 
normal tissues require growth-promoting signals whose production and release 
are carefully controlled. In contrast, cancer cells can sustain proliferative 
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signalling and become masters of their own destinies (Hanahan and Weinberg, 
2011). 
Cancer cells deregulate mitogenic signalling in several ways (Cheng et aI., 
2008; Hanahan and Weinberg, 2011): they can; 
• generate their own proliferative factor ligands; 
• send stimulating signals to induce expression of growth factors from 
normal cells nearby; 
• elevate their sensitivity to some growth factor ligands through 
increasing the receptor proteins at the cell surface. 
1.1.1.2 Evading Growth Suppressors 
In normal tissues, dozens of anti-proliferative signals generated from tumour 
suppressors operate to maintain cellular quiescence and tissue homeostasis 
(Hanahan and Weinberg, 2000). Two famous tumour suppressor genes encode 
the retinoblastoma (RB) and p53 proteins which are central to the regulation of 
proliferation, senescence or apoptosis (Hanahan and Weinberg, 2011). 
The RB protein is a critical gatekeeper of the cell cycle, deciding whether or 
not a cell can proceed through its growth-and division cycle (Burkhart and 
Sage, 2008; Deshpande et aI., 2005; Hanahan and Weinberg, 2011; Lapenna 
and Giordano, 2009). RB pathway receives growth-inhibitory signals, mainly 
from outside of the cell, while p53 is activated by intracellular operating 
systems. In response to stresses, such as DNA damage, oxidative stress (Han 
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et aI., 2008), and deregulated oncogene expression, p53 can activate DNA 
repair proteins, arrest the cell cycle and trigger apoptosis. 
The genes encoding RB and p53 tumour suppressor proteins are functionally 
inactivated in a broad range of cancers. Loss of p53 tumour suppressor 
function occurs in approximately 50% cancers (Vogel stein et aI., 2000). The 
detailed mechanisms of the two suppressors will be described later. 
1.1.1.3 Resisting Cell death 
Tumour cells can evade apoptosis in several ways. The BCL-2 family proteins 
which contain counterbalancing pro- and anti- apoptotic members constitute a 
critical control point in apoptosis regulation (Adams and Cory, 2007; Danial, 
2007). The multiple apoptosis-avoiding mechanisms found in tumour cells 
include: up-regulation of anti-apoptotic proteins (Bcl-2, Mcl-I); down-
regulation of pro-apoptotic factors (Bax, Bim, Puma), increasing expression of 
survival signals and evading the extrinsic ligand-induced pathway (Hanahan 
and Weinberg, 2011). In contrast to apoptosis, which is a barrier to cancer 
development, recent research shows necrosis has tumour-promoting potential 
(Grivennikov et ai., 2010). 
1.1.1.4 Enabling replicative immortality 
In contrast to nonnal cells, which only pass through a limited number of cell 
cycles, cancer cells have limitless replicative potential giving rise to tumours 
(Hanahan and Weinberg, 2011). It has been indicated that telomeres, which 
protect the ends of chromosomes, playa key role in the unlimited proliferation 
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(Blasco, 2005). Telomeres are composed of repetitive DNA sequences and 
protect the end of the chromosome from deterioration or from fusion with 
neighbouring chromosomes (Talks, 2008). Non-immortalized cells gradually 
lose telomeric sequences as a result of incomplete replication (Counter et aI., 
1992). Eventually the shortened telomeres lose the capacity to protect the ends 
of chromosomal DNAs after which cells reach the limit of their replicative 
capacity and progress into senescence. 
Cancer cells have to overcome the telomere shortening to maintain unlimited 
proliferation and the majority (85% - 90%) of malignant cells succeed in doing 
so by up-regulating expression of telomerase, which adds repetitive nucleotide 
sequences to the ends oftelomeric DNA (Bryan and Cech, 1999). 
1.1.1.S Inducing Angiogenesis 
The growth of new blood vessels (the process of angiogenesis) is essential for 
growing tumour tissues to obtain essential nutrients and oxygen. Multiple lines 
of evidence have indicated that counteracting factors with induction or 
inhibition effects regulate the process of angiogenesis (Baeriswyl and 
Christofori, 2009; Bergers and Benjamin, 2003). As the most important and 
well-known angiogenesis inducer, the vascular endothelial growth factor 
(VEGF) can be up-regulated by oncogene signals during an early stage of the 
development of invasive cancers. 
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1.1.1.6 Activating invasion and metastasis 
During the development of most human cancers, some pioneer cells from 
primary tumour masses acquire the ability to penetrate the walls of lymphatic 
and/or blood vessels, circulate through the bloodstream to other tissues, re-
penetrate through the vessel or walls, continue to multiply, and eventually form 
another tumour. The capability for invasion and metastasis are the cause of 
approximately 90% of human cancer deaths (Sporn, 1996). E-cadherin, a key 
cell-to-cell adhesion molecule is the best characterized antagonist of invasion 
and metastasis. Down-regulation and inactivation of E-cadherin are frequently 
detected in human carcinomas (Cavallaro and Christo fori, 2004; Hanahan and 
Weinberg, 2011) 
1.1.1.7 Other hallmarks of cancer 
Conceptual progress in cancer research in the last decade has resulted in two 
emerging hallmarks: deregulating cellular energetics and avoiding immune 
destruction. The first involves the capability to regenerate cellular metabolism 
to support tumour growth more effectively and the second describes the ability 
of cancer cells to avoid immunological destruction by TIB lymphocytes, 
macrophages or natural killer cells. In addition, genome instability and tumour-
promoting inflammation facilitate the acquisition of both core and emerging 
hallmarks and thus are labelled as enabling characteristics. (Hanahan and 
Weinberg, 2011) 
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1.1.2 RB protein and ceO cycle control 
As mentioned previously, cancer cells have to evade growth suppressors to 
enable their unlimited proliferation. RB protein (PRb) is a well known tumour 
suppressor and a critical cell cycle gatekeeper. Mutation of the RB gene is 
common in many types of cancer. This section will describe the mammalian 
cell cycle and the RB pathway. 
1.1.2.1 The mammalian cell cycle 
S phase 
(DNA synthesis) 
M (mitosis) 
EUKARYOTIC 
CELL CYCLE 
Figure 1.2 The mammalian cell cycle. 
Go (cells that 
cease division) 
There are four phases in the mammalian cell cycle (Figure 1.2): S-phase, 
during which DNA is replicated; M-phase, in which the chromosomes are 
separated into two new nuclei in the process of mitosis. These two phases are 
separated by two "Gap" phases, G 1 and G2. Cells prepare for the entering into S 
phase in G) phase and for upcoming events of M phase in G2. Go denotes the 
quiescent state of the cells which withdraw from the active cell cycle. Critical 
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decisions are made by cells in G1 phase on whether to commence a new 
proliferation cycle or proceed from mitosis into a resting state, Go. 
1.1.2.2 eyelins and eyelin-dependent kinases 
During the cell cycle, different Cyclins accumulate and activate cyclin 
dependent kinases (CDKs) at specific times to control the progression of cells. 
Cyclins are so named because their concentrations cycle up and down during 
the cell cycle. They activate CDKs by forming cyclin-CDK complexes which 
send out signals to responder molecules to push forward the growth-and-
division cycle. Each type of cyelin binds one or several specific CDKs: 
CyclinD binds CDK4 or CDK6, CyelinE binds CDK2, CyelinA binds CDKI 
or CDK2 and CyelinB pairs with CDKI . 
B COK1 
p15 
p16 --j 
p18 
. O.COK4 
p19 
COK4/6 
• E-CDK2 
p21 
-----1 A·CDK2 p27 
p57 A-CDK1 
B·CDK1 
I E COK2 A COK2 
Figure 1.3 Cyclins and CDKs in the cell cycle regulation (Adapted from Weinberg, 2007). 
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In mammalian cells, distinct Cyc1in-CDK complexes take part in regulating 
specific cell cycle transitions: Cyc1inD-CDK4/6 for sustaining G 1, CyclinE-
CDK2 for entering into S phase, Cyc1inA-CDK2 for S phase progression, and 
CyclinAlB-CDKI for G21M progression and transition (Figure 1.2). Some 
general CDK inhibitors, which specifically inhibit certain CyclinlCDK 
complexes, are also activated and inactivated at appropriate times during the 
cell cycle. INK4 family proteins (pI5, p16, pl8 and p19) inhibit CDK4 and 
CDK6 by interfering with their association with D-type cyclins, while CiplKip 
family members (P2I, p27 and p57) regulate the activities of Cyclin AlB/E-
CDK complexes (Sherr and Roberts, 1999) (Figure 1.3). In the past two 
decades, extensive research on novel small molecular CDK inhibitors from 
pharmaceutical companies and academics has led to many clinical candidates 
for cancer treatments. CDKs, especially transcription regulator CDK9, have 
been proved to be an ideal drug target. These will be described in detail later. 
1.1.2.3 RB pathway in cell cycle regulation 
As mentioned earlier, cells in GI phase must make a critical decision on 
whether to retreat from the active cell cycle into Go, or go further into late G I 
and the remaining phases of the cycle. This decision is made at a transition 
which is named restriction point (R point) (Figure 1.3 and Figure 1.4). The R 
point occurs a few hours before the GI/S transition in most mammalian cells. 
RB, which was the first cloned tumour suppressor gene, was found to regulate 
the R-point transition and RB mutation was observed in many tumour types 
(Classon and Harlow, 2002). 
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Figure 1.4 The RB pathway and GlIS phases regulation (Adapted from Weinberg, 2007). 
The retinoblastoma protein (PRb) is phosphorylated and dephosphorylated 
during specific phases of the cell cycle (Buchkovich et aI. , 1989) and its 
growth inhibition ability depends on the phosphorylation status. Considerable 
evidence indicates non- or hypo- phosphorylated pRb inhibits cell growth 
through early to mid-G , phase until it becomes hyper-phosphorylated when it 
loses its growth inhibition ability and permits cells to pass through the R point 
into late G, and the other remaining phases of the cell cycle (Goodrich et aI. , 
1991; Weinberg, 1995). Other evidence supports RB's role as a cell-
proliferation regulator in G, phase: RB over-expression arrested cells in G, 
phase (Huang et aI., 1988) while RB deficiency accelerates G, transition 
(Herrera et aI., 1996). 
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It has been indicated that pRb controls the cell cycle progression through its 
repressive effect on the E2F transcription-factor family (Dyson, 1998; 
Weintraub et aI., 1995). Un-phosphorylated or hypo-phosphorylated pRb binds 
to E2Fs, whereas hyper-phosphorylated pRb dissociates from the E2Fs (Figure 
1.4). E2Fs have been shown to regulate the expression of genes required for 
G)-S transition and binding to pRb prevents the E2Fs from acting as 
stimulators of transcription. 
As mentioned above, the phosphorylation status of pRb relates to its binding to 
E2Fs and growth inhibition ability. When the E2F-mediated transcription is 
negatively regulated by pRb, cyclin-CDK complexes regulate the 
phosphorylation of pRb (Figure 1.4). In early/mid G), cyclinD-CDK4/6 
complex ftrst hypo-phosphorylates pRb, which is further phosphorylated at the 
R point by cyclinE-CDK2 complex, leading to its hyper-phosphorylation. In 
addition, the activity of cyclin-CDK4/6 complexes is regulated by INK4 (pIS, 
p16, pl8 and p19) and Cip/Kip (P21, p27 and pS7) family CDK inhibitors 
(Malumbres and Barbacid, 2009; Sherr and Roberts, 1999). 
Two other pRb related proteins, pi 07 and p 130 are also involved in G) 
regulation and repress E2F -mediated gene transcription. These three proteins 
are called pocket proteins because their main sequence similarity resides in a 
"pocket" domain (regions A and B, separated by a spacer) (Figure 1.5) which 
is required for their interaction with E2Fs and many other factors (Classon and 
Harlow, 2002) 
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Figure 1.5 Pocket proteins (Cozar-Castellano et aI. , 2006). 
Although the pocket proteins have similar structure and functions, they are 
expressed at different times during the cell cycle (Figure 1.6). p130 associates 
with E2Fs primarily in Go and p107 is involved in controlling advance through 
late G j and S phase. However, pRb is expressed at a constant level (Classon 
and Harlow, 2002). 
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x 
- RB 
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Figure 1.6 Different expression of pocket proteins throughout the cell cycle (Classon and 
Harlow, 2002). 
Deletion of p107 or p130 has no significant effects on tumour susceptibility 
and mouse embryos without pI07 or p130 grow normally (Mulligan and Jacks, 
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1998). In contrast, RB deficiency is lethal in mouse embryos and tumours were 
detected in RB (+1-) mice (Jacks et aI., 1992; Malumbres and Barbacid, 2001). 
This evidence indicates that mutation of RB but not other pocket proteins 
relates extensively to tumour generation. 
1.1.2.4 Cell cycle deregulation in human tumours 
Mutation of cell cycle regulators occurs frequently in human cancers. 
Molecular analysis has shown the pRb pathway is frequently deregulated in 
most types of human tumours. Lots of abnonnalities lead to disfuctional pRb, 
such as inactivation of RB gene, methylation of RB gene promoter and 
sequestration of pRb by the HPV E7 viral oncoprotein. Other alterations in cell 
cycle regulation involve up-regulation of cyclins, over-expression of CDKs, 
and decrease of general CDK inhibitors (Malumbres and Barbacid, 2001). 
1.1.3 pS3: Policeman of the oncogenes 
The discovery of p53 can be traced back to 1979 (Lane and Crawford, 1979; 
Linzer and Levine, 1979), and p53 was subsequently characterized as a tumour 
suppressor (Finlay et aI., 1989). p53 has been called a "guardian of the genome 
and policeman of the oncogenes" (Efeyan and Serrano, 2007) because of its 
two central roles in coordinating the cellular responses to DNA damage and 
oncogenic signalling. Because DNA damage is widely present in cancer, more 
attention has been paid to oncogenic signalling induced p53. 
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1.1.3.1 p53 mutations and cancer 
Regarded as "the guardian of the genome", p53 regulates the expression of a 
wide variety of genes involved in apoptosis, growth arrest and inhibition of cell 
cycle progression. Intensive research on p53 over the last three decades has 
revealed the crucial role of p53 pathway in cancer prevention and mutations in 
TP53 (the gene encoding p53 tumour suppressor) are found in about half of all 
human cancers (Toledo and Wahl, 2006). Most of the tumour-associated 
mutations in TP53 are point mutations (93 .6%) which lead to single amino-acid 
substitutions, while 95% of the mutations are found in the sequence-specific 
DNA binding region (Figure 1.7) (Vousden and Lu, 2002). Importantly, 28% 
of the mutations occur at only six residues (R175, G245, R248, R249, R273 
and R282) . 
111 1 I II 01 DOl 
to .. .. if 
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Figure 1.7 pS3 structure and location of tumour-associated mutations (Vousden and Lu, 
2002). The numbers above the figure indicate the amino acid residue number. 
Animal studies on mice carrying germ-line p53 mutations indicate that p53 is 
not necessary for normal mouse development but that it is a tumour suppressor 
14 
gene (Jacks et aI., 1994). While all mice lacking both germ-line copies of the 
p53 show normal embryo development, significantly increased mortality and a 
short life span were observed in p53-1- mice, which died mainly from sarcomas 
and lymphomas (Figure1.8). In addition, mice with p53+1- heterozygotes 
bagan to develop tumours at about 250 days of age. 
)l. \ I 
Id l\ I 
Figure 1.8 Effects of pS3 mutation on survival (Jacks et al. ,1994). The survival rates of mice 
with different p53 genotypes are shown as a function of elapsed lifetime in days. 
1.1.3.2 p53 activation 
p53 protein is maintained at low levels and low activity by Mouse Double 
Minute-2 (MDM2) mediated degradation. MDM2 is an important negative 
regulator of the p53 tumour suppressor by ubiquitinating N-terminal trans-
activation domain of p53 (Marine and Lozano, 2010; Piette et ai., 1997). 
MDM2 also binds to the trans activation domain of p53, preventing interaction 
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with the transcriptional machinery. Stabilization of p53 can be induced by a 
variety of cell-physiologic stresses, such as lack of nucleotides, UV and 
ionizing radiation, hypoxia, blockage of transcription and oncogenic signalling 
(Weinberg, 2007). MDM2 is phosphorylated at multiple sites in cells. 
Following stresses, phosphorylation of Mdm2 leads to changes in protein 
function and stabilization ofp53. 
The classic model of p53 activation contains three steps: p53 stabilization, 
DNA binding and transcriptional activation. However, in vivo genetic studies 
show that the traditional model cannot explain all aspects ofp53 activation. To 
solve the problem, a refined model for p53 activation was suggested by Kruse 
and Gu recently (Kruse and Gu, 2009). 
The refined model also consists of three steps: (1) p53 stabilization, (2) anti-
repression and (3) promoter-specific activation (Figure 1.9). In this model the 
second step, anti-repression, in which p53 releases from repression factors 
MDM2 and MDMX is the key step in the physiological activation of p53 
(Kruse and Gu, 2009). 
MDM2 and MDMX (also known as MDM4) are structurally related proteins, 
both of which are required to restrain p53 in a non-redundant manner (Marine 
et aI., 2006). The p53 repression function of MDM2 and MDMX are clearly 
indicated by in vivo studies carried out in mice. Mice lacking either MDM2 
(Montes de Oca Luna et aI., 1995) or MDMX (Parant et aI., 2001) cannot 
survive but the lethality is rescued by inactivation ofp53. 
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Figure 1.9 Refined model for pS3 activation (adapted from Kru e and Gu, 2009). Promoter-
specific p53 activation in vivo includes three key steps: (I) p53 stabilization, (2) anti-
repression and (3) promoter-specific activation. Ac, acetylation; P, phosphorylation; Me, 
methylation; N8, neddylation; S, sumoylation. 
Despite its sequence homology with MDM2, MDMX does not modulate p53 
levels but instead inhibits p53-induced transcription (Marine et aI., 2006). In 
addition, recent studies in mutant mice indicate that repression of p53 is the 
major role of MDMX (Iwakuma and Lozano, 2007). Transcription of p53 
targets can be repressed by both MDM2 and MDMX at p53 promoter regions 
by many different mechanisms, whereas acetylation or phosphorylation of p53 
at specific lysine residues facilitates the release of p53 from the repression 
mediated by MDM2 and MDMX (Kruse and Gu, 2009). 
After release from its repression status, p53 interacts with many cofactors 
which facilitate special p53 targets for DNA repair, cell cyele regulation, 
apoptosis, senescence, autophagy and metabolism (Figure 1.9) (Kruse and Gu, 
2009). For example, the expression of p21 (a potent cyelin-dependent kinase 
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inhibitor) is tightly controlled by p53 through which this protein mediates the 
p53-dependent G1 phase arrest in response to a variety of stress stimuli. 
Importantly, p53 facilitates apoptosis by transcriptional activation of pro-
apoptotic proteins, such as NOXA and PUMA (Nakano and Vousden, 2001). 
1.1.3.3 Policeman of oncogenes 
Oncogenic signalling activates p53 vla the tumour suppressor ADP-
ribosylation factor (ARF) , which interferes with the MDM2/p53 interaction 
and leads to p53 activation (Palmero et aI., 1998; Stott et aI., 1998). In addition, 
oncogenic signalling cannot activate p53 in the absence of ARF in mice 
(Efeyan et aI., 2006). Recent studies also indicate that ARF -dependent 
activation ofp53 rather than DNA damage response ofp53 is critical to cancer 
protection, (Efeyan and Serrano, 2007). In response to DNA damage, apoptosis 
occurred rapidly in cells with p53, whereas cells without p53 also undergo cell 
death by mitotic catastrophe. In contrast, only cells with p53 are eliminated 
through apoptosis or senescence under oncogenic signalling (Figure 1.10). 
18 
A 
DNA + 53 
damage P 
apoptosls 
(rapid, hours) 
~ f i 2 ~ ' 4 4 ~ ~~ . . " 
- p53 , , ~ ~ ••• ~ ~ .0 · 
~ ~ .0 e. mitotic catastrophe 
(delayed, days) 
B ~ ~ • 0 apoptosls ~ ~ ~ : : : ~ : : + p53 ~ ~ ~.••• 0 __ s_e_n_e_s_ce_n_c_8 __ 
~ ~ ~ ~ : e. " . ~ I I .. " " " "
.. " oP53', 
oncogene-drlven 
proliferation 
Figure 1.10 Impact of p53 on cellular fate upon DNA damage or oncogenic signalling 
(Efeyan and Serrano, 2007). In response to DNA damage, apoptosis occurred rapidly in cells 
with p53, wherea cells without p53 also undergo cell death by mitotic catastrophe (A). Under 
oncogenic signalling, cells with p53 are eliminated through apoptosis or senescence; whereas 
cells lacking p53 continue to proliferate (B) . 
One of the major responses to p53 activation is the induction of apoptosis. The 
role ofp53 in apoptosis will be described in the following section. 
1.1.4 Apoptotic and non-apoptotic death in tumour cells 
1.1.4.1 Different types of cell death 
Apoptosis is the process of programmed cell death and the most common and 
best defmed type of cell death. The Bcl-2 family proteins constitute critical 
controllers of apoptosis and the apoptotic pathways will be introduced later in 
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detail. Although resistance to apoptosis is one of the hallmarks of cancer, 
defects in non-apoptotic pathways, which include necrosis, senescence, 
autophagy and mitotic catastrophe are also associated with tumourigenesis 
(Okada and Mak, 2004). The characteristics of different types of cell death are 
summarized in Table 1.1. 
Table 1.1 Characteristics of different types of cell death (adapted from Okada and Mak, 
2004). 
Type of 
Morphological changes 
Biochemical 
Nucleus membrane Cytoplasm 
cell death features 
Apoptosis Chromatin Blebbing Fragmentation Caspase-dependent 
condensation; (formation of 
nuclear apoptotic bodies) 
fragmentation; 
DNA laddering. 
Autophagy Partial Blebbing Increased number Caspase-
chromatin of autophagic independent; 
condensation; vesicles increased lysosomal 
no DNA activity 
laddering 
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Mitotic Multiple Caspase-independent 
catastrophe micronuclei; (at early stage); 
nuclear abnormal 
fragmentation CDKlIcyclinB 
activation 
Necrosis Clumping and Swelling; Increased 
random rupture vacuolation 
degradation of organelle 
nuclear DNA degeneration 
mitochondrial 
swelling 
Senescence Senescence- Flattening and SA-p-gal activity 
associated increased 
heterochromatic granularity 
foci 
Senescence is the phenomenon by which cells lose the ability to divide when 
the telomeres are not long enough to protect their chromosomes. Some 
morphological changes, such as flattened cytoplasm and increased granularity 
can be observed in senescent cells (Okada and Mak, 2004). Induction of 
senescence-associated p-galactosidase (SA-p-gal) activity was reported to be a 
biomarker of senescence and can be used to identify senescence (Dimri et aI., 
1995). Senescence also occurs under tumourigenic stresses and contributes to 
tumour suppression (Campisi, 2001). The senescence programme usually 
requires the function of p53 and the RB pathway as well as CDK inhibitors, 
such as p21 and p16 (Sage et aI., 2003; Stein et aI., 1999). 
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In contrast to naturally occuning apoptosis, necrosis is an unregulated process 
of traumatic cell destruction with special morphological features (Table 1.1), 
such as organelle degradation, membrane swelling and rupture (Okada and 
Mak, 2004). During apoptotic cell death, a dying cell turns into an almost-
invisible corpse which is consumed immediately by its neighbours. Conversely, 
necrotic cells have bloated bodies, releasing their components into the local 
tissue environment (Hanahan and Weinberg, 2011). 
Autophagy is a form of non-a pop to tic and non-necrotic cell death involving the 
degradation of a cell's own components within lysosomes. It helps to maintain 
the balance between synthesis, degradation and recycling of cell components. 
Although autophagy was first described in the 1960s, its detailed processes and 
mechanisms are still unclear (Stromhaug and Klionsky, 2001). The distinct 
morphology is summarized in Table 1.1, which involves an increased number 
of autophagic vesicles and cell blebbing. 
The M phase of the cell cycle can be divided into two processes: mitosis and 
cytokinesis. During mitosis, sister chromatids are aligned and then separate 
into two daughter cells with the cytoplasm being partitioned into those cells 
during cytokinesis. Mitotic catastrophe is a cell death modality that is caused 
by aberrant mitosis (Kepp et aI., 2011). Multinucleate and uncondensed 
chromosomes are typical morphological characters which are different from 
apoptosis, necrosis and autophagy (Okada and Mak, 2004). 
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1.1.4.2 BcI-2 family proteins and apoptosis 
The programmed cell death (apoptosis) of unwanted or damaged cells is 
essential to maintain normal development through two programmes (extrinsic 
and intrinsic) which finally activate the cysteinyl aspartate - specific protease 
(Caspase) family, leading to cell eleavage and death (Danial, 2007). The 
extrinsic pathway operates downstream of death receptors, such as the tumour 
necrosis factor (TNF) and Fas receptor family, resulting in the formation of the 
death-inducing signalling complex (DISC), which in tum activates caspase-8. 
In the intrinsic pathway, caspase activation is under the regulation of the 
apoptosome, which is composed of apoptotic protease - activating factor-l 
(APAF-l), caspase-9 and cytochrome c. 
The Bcl-2 family can be divided functionally into anti-apoptotic proteins (Bel-
2, Bel-XL, Bel-w, Mel-l and AI) and pro-apoptotic proteins (BAK, BAX BIM, 
BID, PUMA, NOXA, BAD, HRK, BMF, BIK)(Lessene et at, 2008) (Figure 
1.11). Based on the sequence and structural features, the family comprises 
multidomain proteins and BH3-only proteins. Multidomain proteins share four 
Bcl-2 homology (BH) domains while BH3-only pro-apoptotic proteins show 
sequence homology only within a single a helical segment, the BH3 domain 
(Lessene et aI., 2008). 
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Figure 1. 11 The Bcl-2 protein family (Lessene et aI. , 2008). This family can be divided 
functionally into anti-apoptotic proteins (green boxes) and pro-apoptotic proteins (red boxes). 
Based on the sequence and structure features, the family comprises multidomain proteins (a) 
and BH3-only proteins (b). 
Interactions between pro-survival and pro-apoptotic proteins control the switch 
of cell death through governmg mitochondrial outer membrane 
permeabilization (MOMP) and release of cytochrome c into the cytoplasm. 
Pro-apoptotic proteins BAK and BAX are essential for apoptosis through 
forming pores capable of releasing cytochrome c in the mitochondrial outer 
membrane (MOM) (Danial and Korsmeyer, 2004). Once cytochrome c is 
released, it binds to the apoptotic protease - activating factor-l (AP AF -1) to 
facilitate the formation of apoptosome, which is in charge of caspase activation. 
There are several models concerning the pro- or anti- apoptotic effects of the 
Bcl-2 family. In one theory, anti-apoptotic proteins, such as Bcl-2 and Bcl-XL' 
bind to the BH3 domain of pro-apoptotic proteins BAK or BAX and inhibit 
their activity. As sensors of cellular stress, BH3-only proteins are the natural 
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antagonists of anti-apoptotic proteins (Lessene et aI., 2008; Willis et aI., 2007) 
and they are functionally grouped as pro-apoptotic proteins for facilitating 
BAK and BAX (figure 1.12). Importantly, tumour suppressor p53 facilitates 
apoptosis by transcriptional activation of pro-apoptotic proteins including 
BH3-only proteins NOXA and PUMA (Nakano and Vousden, 2001). 
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Figure 1.12 Intrinsic apoptotic pathway (adapted from Dania) and Korsmeyer, 2004). See 
text for details. 
In addition to their roles in the mitochondria, Bcl-2 family members BAK and 
BAX induce Ca2+ release from the Endoplasmic Reticulum, which is involved 
in regulating the threshold of apoptosis (Danial, 2007; Rong and Disteihorst, 
2008). 
As one of the most important anti-apoptotic proteins, Mcl-l plays two main 
roles in the cellular apoptosis machinery (Akgul, 2009). Firstly, Mcl-l may 
function as an anti-apoptotic factor by sequestering Bak on the outer 
mitochondrial membrane (OMM) to inhibit Bak oligomerization and 
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cytochrome c release from mitochondria. Secondly, Mcl-l could display its 
pro-survival functions by heterodimerizing with activator BH3-only proteins, 
such as tBid, PUMA and Bim. Importantly, Mcl-l has a short half-life and is a 
highly regulated protein. It's rapidly down-regulated during apoptosis while its 
expression is induced by survival and differentiation signals. Moreover, 
specific knockdown of Mcl-l expression by RNA interference resulted in 
induction of apoptosis in cancer cell lines (Potier et aI., 2011), indicating Mc1-I 
could be an ideal target for cancer therapy. 
1.1.4.3 Caspase family and cell death 
Caspases (cysteine-aspartic proteases) are a family of cysteine proteases of 
which at least seven (caspase 2, 3, 6, 7, 8, 9 and 10) contribute to cell death. 
These caspases can be divided into two groups: the initiator caspases (2, 8, 9 
and 10) and the effector caspases (3, 6 and 7) (Kroemer and Martin, 2005). 
Effector caspases further cleave other protein substrates and trigger the 
apoptotic process. 
Although caspase activation has frequently been viewed as a sign of apoptosis, 
caspase inhibition is not always enough to stop cell death and often leads to 
morphology changes (Chipuk and Green, 2005). The relationships between cell 
death and caspase activation have been classified into 3 groups: cell death 
through caspase activation, cell death with caspase activation and cell death 
without caspase activation (Figure 1.13) (Kroemer and Martin, 2005). As 
shown in Figure 1.13, death with caspase activation and death without caspase 
activation are classified as caspase-independent death. 
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Figure 1.13 Relationship between caspase dependency and cell death (Kroemer and Martin, 
2005). 
1.2 Preclinical cancer drug discovery 
The majority of anti-cancer drugs on the market were discovered either by 
chance, for example alkylating anti-neoplastic agents or by screening 
programmes, such as paclitaxel. However, selectivity is a main issue for these 
agents. For example, genotoxic drugs which are widely used in chemotherapy 
for cancer treatment induce general DNA damage in cancer cells but are also 
highly toxic to normal tissues. Therefore, new and better anti-cancer agents are 
urgently needed for cancer treatment. Recent research into the fundamental 
biochemical characteristics of tumour cells has provided a rational approach to 
the drug design process and the combination of rational drug design and 
modem screening techniques is being used to identify compounds against 
specific cancer-related targets (Thurston, 2006). 
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The discovery of modem anti-cancer agents is a time-consuming and expensive 
process, which consists of preclinical discovery and clinical development. The 
typical preclinical cancer drug discovery cascade is shown in Figure 1.14. 
Target identification and validation 
1 
I Screeningfor key candidates 
1 
I Target inhibition in tumour cells 
1 
In vivo antitumour efficacy and toxicity 
1 
I Clinic compound selection I 
1 
I Formulation and manufacture I 
Figure 1.14 The preclinical cancer drug discovery cascade (adapted from Neidle, 2008) 
1.2.1 Target identification and validation 
The first step of developing a new drug is target identification and validation 
(figure 1.14). A good target for cancer should be effective and safe. The best 
approach to develop anti-cancer drugs is targeting the hallmarks of cancer, as 
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illustrated in Figure 1.15. Drugs that inhibit one of the 6 classic hallmarks 
(Figure 1.1) as well as the enabling characteristics and emerging hallmarks of 
cancer have been in clinical trials or approved for clinical use (Weinberg, 
2007). As highlighted in Figure 1.15, inhibition of cell cycle CDKs (the master 
regulators of the cell cycle) may conquer the proliferative disorder of cancer, 
and transcriptional CDK9 inhibitors may induce apoptosis in tumour cells by 
down-regulation of anti-apoptotic proteins, such as Mcl-l and Bcl-2 (section 
1.3.3). 
Aerobic glycolysis 
Inhibitors 
PARP 
Inhibitors 
ReSISting 
cen 
death 
Ge 
tn ta 
mulat.,n 
Sustain ng 
pro 1 1 ~ ' t ' a b v e e
.ignal'ng 
Evading 
growth 
suppreSSOfS 
1M'" '"'9 Ac\.vat,ng 
anglOg neSis ,nva. & 
I'T'If'I ~ t a s s
Immune activating 
anti-CTLA4 mAb 
Enablng 
replocahve 
Immor1al,ty 
Telomerase 
Inhibitors 
Selective anti-
inflammatory drugs 
Figure 1.15 Cancer specific targets (Adapted from Weinberg, 2007). The drugs Ii ted are 
only illustrative examples. Many other drug candidates with different molecular targets are 
under development for most of these hallmarks. 
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Once an ideal target is chosen, it needs to be fully validated. Validation 
techniques include knockdown or knockout of target protein expression using 
in vitro methods (antisense RNA and small interfering RNA - siRNA, etc.) and 
animal models (transgenic animals, etc.) (Hughes et aI., 2011). Antisense RNA 
is single-stranded RNA which is complementary to a messenger RNA (mRNA). 
By using antisense technology, the synthesis of a target protein can be blocked 
through translational inhibition of mRNA when binding to the antisense 
oligonucleotide (Henning SW, 2002). Recently, siRNA (a class of short 
double-stranded RNA molecules) has been widely used for target validation. 
The siRNAs induce cleavage of their target mRNA and prevent it from being 
used as a translational template (Castanotto and Rossi, 2009). As an attractive 
validation tool in vivo, transgenic animal technology (knockout or knockin) 
allow the observation of the phenotype of specific gene manipulation in whole 
animals. 
It has been realized that dominant negative expression would be more effective 
in blocking some enzymatic inhibitors, such as CDK9 (De Falco et aI., 2000). 
In addition, the best proof for target validation might be generating a genetic 
variant cell line based on the hypothetical mechanism that is resistant to the 
inhibitors. For example, cells expressing stable Mcl-l mRNA or, even better, 
cells with powerful CDK9 that cannot be inhibited by the drug are suitable for 
validation of CDK9 inhibitors. 
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1.2.2 Lead identification and optimisation 
After target identification and validation, the next step in the drug discovery 
process is to identify 'hit' molecules by means of screening assays. There are 
many screening methods, reviewed by JP Hughes etc. (Hughes et aI., 2011), 
including: high throughput, focused screen, fragment screen, structural aided 
drug design, virtual screen, physiological screen and NMR screen (Table 1.2). 
In high throughput screening (HTS), an entire compound library is screened 
against the drug target in 384 -, 1536 -, or 3456 - well plates. More than 
100,000 compounds can be screened in one day on a routine basis. For 
compounds with similar structures to molecules for which the target has been 
identified, focused or knowledge-based screening is a cheaper and effective 
method. In Chapter 3, the development of a cell-based focused screening 
cascade is described which is able to classify compounds and identify effective 
transcription CDK (CDK7 and especially CDK9) inhibitors from analogues of 
reported compounds. Other screening methods shown in Table 1.2 are also 
widely used in both industry and academia. Additionally, in order to predict the 
in vivo absorption, distribution, metabolism and elimination (ADME) of lead 
compounds, high-throughput in vitro assays were performed for the 
physicochemical determination of aqueous solubility, lipophilicity (LogP), pKa 
and membrane permeability (Neidle, 2008). 
Table 1.2 Screening strategies (adapted from Hughe et aI., 2011). 
Screen 
High 
throughput 
Description Comments 
Large numbers of compounds Large compound collections often run by 
analy ed in an assay generally big pharma but smaller compound banks 
designed to run in plates of 384 can also be run in either pharma or 
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Focused 
screen 
Fragment 
screen 
Structural 
aided drug 
design 
Virtual screen 
Physiological 
screen 
NMRscreen 
wells and above 
Compounds previously 
identified as hitting specific 
cia ses of targets (e.g. kinases) 
and compounds with similar 
structures 
Soak small compounds into 
crystals to obtain compounds 
with low mM activity which 
can then be used as building 
blocks for larger molecules 
Use of crystal structures to 
help design molecules 
Docking models: interogation 
of a virtual compound library 
with the X-ray structure of the 
protein or, if have a known 
ligand, as a base to develop 
further compounds. 
A tissue-based approach for 
determination of the effects of 
a drug at the tissue rather than 
the cellular or subcellular 
level , for example, muscle 
contractility 
Screen small compounds 
(fragment) by soaking into 
protein targets of known 
crystal or NMR structure to 
look for hits with low mM 
activity which can then be used 
as building blocks for larger 
molecules 
academia which can help reduce costs. 
Companies also now trying to provide 
coverage across a wide chemical space 
using computer assisted analysis to 
reduce the number of compounds 
screened. 
Can provide a cheaper avenue to finding 
a hit molecule but completely novel 
structures may not be discovered and 
there may be difficulties obtaining a 
patent position in a well-covered IP area 
Can join selected fragments together to 
fit into the chemical space to increase 
potency. Requires the availablilty of a 
crystal structure 
Often used as an adjunct to other 
screening strategies within big pharma. 
Usually a compound is docked into the 
crystal and this used to help predict 
where modifications could be made to 
provide increa ed potency or selectivity 
Can provide the starting structures for a 
focused screen without the need to use 
expensive large library screens. Can also 
be used to look for novel patent space 
around existing compound structures 
Bespoke screens of lower throughput. 
Aim to more closely rrurruc the 
complexity of tissue rather than just 
looking at single readouts. May appeal to 
academic experts in disease area to 
screen smaller number of compounds to 
give a more disease relevant readout 
Use of NMR as a structure determining 
tool 
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1.2.3 Target confirmation in tumour cells 
After the screening programme, lead compounds are then evaluated using in 
vitro tumour cell lines. By testing against a panel of different tumour cell lines, 
the selective cytotoxicity of a compound toward a particular tumour type may 
be determined (Thurston, 2006). The US National Cancer Institute (NCI) 
developed 60 human tumour cell lines which are derived from 9 tumour types 
in late 1980s and used them for drug discovery (Shoemaker, 2006). Until now, 
more than 30,000 compounds have been tested. It has been demonstrated that 
compounds with a similar cell growth inhibition mechanism usually show 
similar patterns of activity against the NCI 60 cell lines (Paull et aI., 1989). 
Based on this finding, the NCI 60-cell-line panel also provides an algorithm 
called COMPARE which has been successfully used to predict the mechanisms 
of new compounds (Zaharevitz et aI., 2002). 
Detailed mechanism studies are also performed in tumour cell lines to confirm 
the targets of lead compounds. For example, in order to identify new CDK9 
inhibitors, the phosphorylation status of Ser 2 site of RNA polymerase n 
(CDK9 phosphorylation site) and reduction of anti-apoptotic protein Mc1-1 can 
be tested by western blots (Liu et aI., 20 11 b) 
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1.3 Targeting eyelin dependent kinases for cancer 
therapy 
1.3.1 Kinases 
Kinases are enzymes that transfer phosphate groups from molecules with high 
energy (ATP, etc.) to specific substrates in a process known as phosphorylation. 
The largest groups of kinases are protein kinases, which regulate cell function 
by modifying the activities of functional proteins. They regulate activity, 
location and stability of many proteins through the addition of a phosphate 
group (Jans and Hubner, 1996). 
Among the 518 human protein kinases identified, 478 have similar catalytic 
domains which are related in sequence. Based on sequence similarity and 
biochemical function, the 478 protein kinases are classified into 7 major groups. 
Based on different phosphorylation site, protein kinases can also be divided 
into 2 categories which contain kinases which phosphorylate proteins on 
tyrosine residues (the tyrosine kinases, TK group) or kinases which 
phosphorylate primarily on serine and threonine residues (the other six groups). 
More than 100 kinases in the sub-families of the human protein kinase tree 
have not been characterized yet. However, the relationship shown on the tree 
can be used to predict their substrates and biological functions. 
Kinases have become one of the most intensively studied drug targets and more 
than 30 distinct kinase targets have been developed to the level of Phase I 
clinical trials (Zhang et aI., 2009). As mentioned earlier, cancer cells can evade 
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cell growth suppressors and apoptosis. Therefore, cyelin-dependent kinases 
(CDKs), which are critical regulators of cell cycle progression and RNA 
transcription, are ideal targets for cancer treatment. 
1.3.2 Cyelin dependent kinases (CDKs) 
CDKs, one of the most extensively studied kinase groups in the family of 
serine/threonine (Ser/Thr) protein kinases, phosphorylate serine and threonine 
amino acid residues in specific sequences of numerous proteins, particularly 
those involved in mitosis and cell cycle division when associated with their 
cyclin complexes. Cdc2 (CDKI) was first discovered to regulate the cell cyele 
in yeast. To date, 13 CDKs and 25 proteins with homologous cyelin boxes 
have been found in the human genome and the function of 10 the human CDKs 
and their associated complexes have been identified (Figure 1.16) (Knockaert 
et aI., 2002). 
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Figure 1.16 The specific complexes and functions of 10 human CDKs which have been 
identified (Knockaert et aI., 2002)_ 
Most CDKs are activated by association with cyclins, fonning CDK complexes. 
These heterodimeric complexes can phosphorylate various substrates involved 
in transcriptional regulation (CDK7, CDK8, CDK9, and CDKll), and cell-
cycle progression (CDKl, CDK2, CDK4, CDK6, and CDK7), as well as 
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intravascular signalling (CDKS) (Knockaert et aI., 2002; Malumbres et aI., 
2008). 
1.3.2.1 Cell cycle regulation CDKs 
As described before, distinct Cyclin-CDK complexes take part in regulating 
different cell cycle transitions in mammalian cells. By phosphorylation of the 
Rb protein, CyclinD-CDK4/6 maintains G I, CyclinE-CDK2 is required for 
entering S phase, CyclinA-CDK2 for S phase progression, and CyclinAlB-
CDKI for G21M transition (Figure 1.3). 
CyclinD binds CDK4/6 to form CyclinD-CDK4/6 complex which is 
responsible for the flrst phosphorylation of tumour suppressor protein Rb in G I 
phase. Subsequently, CyclinE is synthesized and interacts with the cell cycle 
checkpoint kinase CDK2. The activated cyciinE/CDK2 complex drives the cell 
cycle from G 1 to S phase. Selective CDK4 inhibitors are expected to block cell 
cycling by imposing a G 1 block in an Rb-dependent manner (Toogood et a1.. 
2005). When Rb is phosphorylated by CyclinD-CDK4/6 or CyclinE-CDK2, it 
detaches from E2F transcription factors, allowing E2F to activate the 
transcription of genes required for S-phase (Classon and Harlow, 2002; 
Ezhevsky et al., 200 I). One of the genes transcribed by E2F is CyclinE itself, 
causing a positive feedback cycle as CyclinE accumulates. 
Cyclin B is made in G2 and M-phases (Coverley et aI., 2002). It combines with 
CDKI to form the major mitotic kinase MPF (M-phase Promoting Factor), 
which is a heterodimeric protein that stimulates the mitotic and meiotic cell 
cycles. Degradation of Cyclin-B, followed by MPF inactivation, is required for 
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exit from mitosis. Previous work suggests that Cdk2 may facilitate 
accumulation of cyclin B and contribute to G21M progression (Lukas et aI., 
1999). Inhibition ofCDK2 also results in 02 phase arrest (Hu et al., 2001). 
Cell cycle CDK inhibitors have been developed as potential new cancer drugs 
based on the premise that they should counteract the unchecked proliferation of 
transformed cells by modulating the functions of CDKs in the regulation of the 
cell cycle. In recent years, the conventional understanding of how CDKs 
function and their role in the cell cycle has been challenged. The observation 
that cancer cell lines and some embryonic fibroblasts lacking CDK2 proliferate 
normally, and that knockout mice are viable (Barriere et aI., 2007; Berthet et aI., 
2003), suggest CDK2 performs non-essential roles and that other CDK 
paralogues substitute in cell cycle control. In addition, the redundancy of 
CDK4 and 6 was also suggested by null mammalian cells that enter the cell 
cycle, and S phase, normally (Malumbres et aI., 2004). It has been 
demonstrated that mouse embryos deficient in all interphase CDKs develop to 
mid-gestation as CDKI can form complexes with all cyclins and consequently 
phosphorylates pRb, thus activating E2F mediated transcription of proliferation 
factors (Santamaria et aI., 2007). Elimination of CDKs 2, 3, 4 and 6 in these 
investigations shows that expression levels ofCDKI, and the cell cycle cyclins, 
appears to be unchanged, that catalytic activity of CDKI is sufficient for cell 
cycle progression and that CDKI can execute all necessary events for cell 
division. Moreover, specific CDKI depletion in some cancer cells results in 
accumulation of cells with 021M DNA content, but causes only minimal cell 
death, and CDK2/cyclin B is readily detected in cells deleted for CDK I to 
facilitate G21M progression (Cai et aI., 2006b). Taken together, these studies 
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suggest that specifically targeting individual cell cycle CDKs may not be an 
optimal therapeutic strategy. 
1.3.2.2 Transcriptional regulation CDKs 
RNA polymerase (RNAP) makes a copy of a gene from the DNA to mRNA 
during a process called transcription. RNAP II, which is a 550 KDa complex of 
12 subunits, is the most studied type of RNAP in eukaryotic cells. 
In contrast to CDKs involved in cell cycle transitions, cyclinH-CDK7 and 
cyclinT -CDK9 complexes regulate RNAPII transcription. The carboxy-
terminal domain of human RNA polymerase II typically consists of 52 repeats 
of the sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser. CDK7 first phosphorylates the 
Ser-5 residues of the CTD in the heptapeptide repeats Y1S2P3T4S5P6S7 as 
part of transcription initiation. The positive transcription elongation factor b (P-
TEFb), which is composed of cyclinT-CDK9, phosphorylates the Ser-2 in the 
heptapeptide repeats and facilitates transcriptional elongation (Figure 1.17). 
initiation c 0 K -9 elongation 
Ser2 
Figure 1.17 The transcription process regulated by CDKs. CDK7/cyclin H first 
phosphorylates R AP 11 CTD at Ser 5, which allows the dissociation ofTFIIH from R AP II 
and promotes the initiation of R AP II. This pho phorylation is also necessary for recruitment 
of the Capping enzyme (C. E.) which binds to R AP II to generate a 5'cap for mRNAs. 
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Phosphorylation of CTD Ser 2 by CDK9 facilitates transcription elongation. (Adapted from 
(Walker, 2006). 
Transcriptional inhibitors can be used for selective cancer therapy (Figure 
1.18). Usually, normal cells have relatively low sensitivity to apoptotic stimuli 
and oncogenic transformed cells show increased sensitivity to apoptotic signals. 
However, this apoptotic sensitivity is counteracted by the induction of anti-
apoptotic proteins, whose transcription procedures are tightly dependent on the 
activity of RNAPII. Inhibition of RNAPII transcription activity would result in 
a reduction of the anti-apoptosis proteins, which ftnally leads to apoptosis of 
tumour cells. In contrast, normal cells should not be affected by decreased 
levels of anti-apoptosis proteins (Koumenis and Giaccia, 1997). 
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Figure 1.18 Targeting transcription as a potential cancer therapy (adapted from Koumenis 
and Giaccia, 1997). Oncogenic Iran formation usually enhances the sensitivity of cells to 
apoptotic signals (A). However, anti-apoptotic proteins expressed in cancer cells inhibit the 
function of apoptotic signals (Al) and enable cancer cell survival. Transcriptional inhibitors 
recover the sensitivity of cancer cells to apopto i by reducing anti-apoptotic proteins and 
increasing p53 tumour suppressor. 
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As described before in section 1.1.3, p53 induces apoptosis or other effects as a 
transcription regulator and the transcription inhibition by CDK9 is supposed to 
counteract the function of p53. Paradoxically, phannacological inhibition of 
mRNA synthesis by P-TEFB leads to global inhibition of mRNA synthesis but 
activation of the p53 pathway through p53 accumulation and expression of 
specific p53 target genes (Gomes et a1., 2006). 
1.3.3 Cyelin Dependent Kinase 9 
CDK9 is unique in apparently lacking cell-cycle-related roles (Wang and 
Fischer, 2008). It was originally named PIT ALRE and identified in a human 
cDNA library screen in 1994 (Grana et aI., 1994). The region ofCDK9 shares 
33 - 47 % amino acid identity with other CDKs. Two isofonns of CDK9, 
CDK942 and CDK955 have been identified with molecular weights of 42 and 55 
kD respectively. The CDK955 gene contains a TA TA-box promoter upstream of 
the common CDK942 promoter (Figure 1.19). CDK9ss also exhibits a unique 
117 amino acid N-tenninal extension with a proline-rich region and a glycine-
rich region followed by 372 residues identical to CDK942 (Grana et a1., 1994). 
The expression ratio of CDK942 to CDK955 varies in different tissues (Marshall 
and Grana, 2006). 
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Figure 1.19 Gene and sequence of human CDK9 isoforms (Marshall and Grana, 2006) . (A) 
CDK942 has a TAT A-less promoter and CDK9" contains an upstream T AT A-containing 
promoter. (8) CDK942 consists of 372 amino acids, whereas CDK955 exhibits a unique 117 
amino acid N-terminal domain (Pro-Gly rich) followed by 372 residues identical to CDK942 · 
Both CDK9 isoforms contain the ATP-binding site (ATP-BS), the PSTAIRE-like motif 
PITALRE, and the putative nuclear localization signal (NLS). 
1.3.3.1 CDK9 and cancer 
As described earlier, resisting cell death is a general hallmark of cancer. Cancer 
cells are "addicted" to transcription because they need continuous production 
of anti-apoptotic proteins such as Bel-2 and Mel-} (Wang and Fischer, 2008) . 
Therefore, a therapeutic window for the use of transcriptional CDK inhibitors, 
especially CDK9, could be predicted. Targeting CDK9 regulated transcription 
can recover the sensitivity of cancer cells to apoptosis by reducing anti-
apoptotic proteins (Figure 1.20). Through down-regulation of MDM2, an 
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important negative regulator of p53, CDK9 inhibition can stabilize p53 
(Demidenko and Blagosklonny, 2004), which also lead to apoptosis (Figure 
1.20). 
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Figure 1.20 Apoptosls Induced by CDK9 Inhibition. In the intrinsic pathway, apoptosis occurs 
after the release of cytochrome C from mitochondria, which is regulated by Bc1-2 family members 
including pro- and anti- apoptotic proteins. CDK9 activates pro-apoptotic proteins BAK and BAX 
through down-regulation of anti-apoptotic proteins (Bcl-2, BcI-XL, Mc1-I). By reducing MDM2 levels, 
CDK9 inhibition stabilizes pS3, which could also induce apoptosis. 
1.3.3.2 CDK inhibitors in clinical trials 
Since inhibition of CDK9 has emerged as a potential cancer therapy, numerous 
CDK inhibitors have been developed. Many of them were originally designed 
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to target cell cycle CDKs, but it was found later that their anti-tumour activity 
was consistent with cellular CDK9 mediated RNAPII inhibition. This is why 
these drug candidates are cross-reactive toward multiple CDKs. 
Many different classes of A TP competitive CDK inhibitors have been 
developed, (Rizzolio et a1., 2010). Currently, some of them are under clinical 
evaluation (Table 1.3). 
Flavopiridol 
The first CDK inhibitor to enter clinical trials was flavopiridol, which is a 
semi-synthetic flavonoid with potent inhibitory activity against a variety of 
cyclin-dependent kinases (CDKl, 2, 4, 6, 7 and 9). Being the most potent 
known inhibitor of CDK9, flavopiridol binds tightly to the A TP binding site of 
CDK9, with a Ki value of 3 nM (Shapiro, 2006). 
At least 15 trials have been done in phase I and phase II aimed at evaluating the 
anti-tumour efficacy of flavopiridol (Lu et a1., 2004). A phase I study in 
chronic lymphocytic leukemia (CLL) demonstrated marked activity with a 40% 
overall response rate (Phelps et aI., 2009). In CLL cells, flavopiridol decreases 
transcription by inhibiting the phosphorylation of CTD of RNAPII at ser2 and 
ser5 (Chen et a1., 2005). Since CLL cells are largely quiescent and normally do 
not need the cell cycle CDKs, the effect of flavopiridol is believed to be mainly 
through CDK9 inhibition, leading to down-regulation of anti-apoptotic proteins, 
such as Mcl-l (Chen et aI., 2005). 
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Table 1. 3 Small-molecule CDK iohiblton with activity against CDK9 in clinical trials 
(Rizzolio et aI., 2010), 
r----.--,-----------------
('om.,ollncl 
F).wop,"d". 
(R) 
l'O'>('o\'llml! 
AT7519 
R'i,.7 
SC'H 7n96<; 
'II II('IUI to 
o-n 0 (j 
l : j - ~ · · :-"H'- ~ ' H H
o rJ \ 
I !I: 
fi 
011 0 
II 
II 
11 
45 
Discouraging results were obtained when flavopiridol was administered as a 
single agent in phase II clinical trials for multiple myeloma (Dispenzieri et a1., 
2006), metastatic malignant melanoma (Burdette-Radoux et aI., 2004) and 
endometrial carcinoma (Grendys et a1., 2005). The major toxicity effects of 
flavopiridol include diarrhoea and myelosuppression, while the main problems 
which limit the clinical use of flavopridol as a single agent are due to its poor 
absorption and narrow therapeutic window. Currently, a number of clinical 
trials for a combination of flavopiridol with other drugs are in progress. 
Flavopiridol has also been reported to target DNA, intercalating into the 
molecule and comparison analysis reveals that flavopiridol shares similar 
mechanisms of action with DNA intercalating or damaging agents, such as 
ecteinascidin 729, chromomycin A3, actinomycin D (Bible et aI., 2000). 
However, the biological significance of DNA binding has not been determined. 
In addition, the cytotoxicity of flavopiridol was reported to have no cell type 
selectivity (Liu et aI., 2011b) and the reason for that needs to be further 
investigated. 
Roscovitine 
Roscovitine (Seliciclib) is a purine derivative that inhibits CDK2, 7 and 9 
(McClue et al., 2002). Similar to flavopiridol, rescovitine inhibits RNAPII 
CTD phosphorylation, which results in a decrease in Mc1-1 and other anti-
apoptotic proteins in CLL cells (Alvi et aI., 2005; Hahntow et aI., 2004). In 
contrast to flavopiridol, roscovitine shows a higher degree of selectivity, 
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targeting only 11 kinases (Ki 5J.1M) across a panel of 317 kinases (D'Andrea et 
a1.,2005). 
Several phase I and phase II clinical trials for roscovitine alone or with other 
agents have been done in non-small cell lung cancer (NSClC) and other 
malignant solid tumours. The common side effects are hypokalemia, 
hyponatremis, hyperglycemia, elevated gamma-glutamyl transpeptidase and 
skin rash (Rizzolio et aI., 2010). 
SNS-032 
SNS-032 (formerly known as BMS-387032), is a thiazole derivative which was 
originally synthesized by Bristol-Myers Squibb Pharmaceutical Research 
Institute as a selective inhibitor of CDK2 (Misra et aI., 2004). It was later 
realized that SNS-032 was also potent against CDK9 (ICso = 4 nM) and CDK7 
(ICso = 62 nM) after this compound was licensed by Sunesis Pharmaceuticals. 
Phase I trials of SNS-032 against advanced solid tumours (Heath et aI., 2008) 
and advanced B-lymphoid malignancies, including CLl and multiple myeloma 
(Chen et aI., 2009). Transcription inhibition by SNS-032 reduced anti-apoptotic 
proteins Mc1-1 and XIAP, resulting in cell death. Removal of SNS-032 
reactivated RNAPII, leading to re-synthesis of Mcl-l (Chen et aI., 2009). 
1.3.3.3 Discovery of novel CDK9 inhibitors 
Structure-based design and analogue modification are often used to identify 
kinase inhibitors. Most of the CDK inhibitors under evaluation are A TP 
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competitive molecules. The x-ray crystal structure ofCDK2 indicates that three 
regions in the ATP-active binding domains are crucial for ATP mimetics: the 
hinge region, the ribose binding domain and the hydrophobic binding pocket. 
The hydrophobic binding pocket plays the key role for designing inhibitors 
with specificity for individual CDKs (Wang et aI., 2004). 
Figure 1.21 The crystal structure of the CDK9 (green) /cyclin TI (brown) complex 
(Baumli et aI. , 2008). The phospho-threonine residue in the activation segments is indicated by 
the red dot. 
The structure of the A TP binding domain is particularly conserved among the 
CDKs, especially between CDK2 and CDK9. Recently, the crystal structure of 
CDK9/Cyclin TI has been determined (Baumli et aI., 2008) (Figure 1.21), 
showing a relative 26 0 rotation of Cyelin T1 with CDK9. A TP antagonistic 
CDK9 inhibitors, such as flavopiridol, bind to the A TP binding site in CDK9 
and induce un-anticipated structural rearrangement. 
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Our novel CDK9 inhibitors, based on the structure of 2, 4, 5-trisubstituted 
pyrimidine, are designed as ATP antagonists against the A TP binding pocket of 
the kinase domain (Figure 1.22). Inspection of the binding mode of this class 
of CDK inhibitors in the ATP pocket of CDK2 indicated that they bound 
similarly to A TP itself. 
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Figure 1.11 Similar binding modes of 1,4,S-trisubstituted pyrimidine and ATP to ATP 
binding pocket of CDK1. A The three hydrogen bonds in this ATP-CDK complex are: NH2: 
Glu 81 CO; pyrimidine Nl: Leu 83 NH; pyrimidine H6: Leu 83 CO. B The proposed binding 
of2.4,5-trisubstituted pyrimidine to the ATP binding pocket ofCDK2. RI binds to Glu 81 CO. 
R2 and R3 are designed to improve the potency and selectivity against CDK9. 
1.4 Aims and objectives 
Over the past decade, an intensive search for small molecule CDK inhibitors 
has resulted in development of several CDK inhibitors in clinical trials. A 
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novel class of 2,4,5-trisubstituted pyrimidine CDK inhibitors has been 
developed in our group. The project described was undertaken with the 
following specific aims: 
1) To develop a screening cascade to classify compounds on the basis of 
their effects on proliferation, transcription, cell-cycle regulation and 
apoptosis. This cascade could then be used to screen and identify lead 
compounds. 
2) To study the detailed cellular mode of action for lead compounds. 
Confirming the primary cellular mechanism of action. 
3) To select a pre-clinic candidate using the drug flavopiridol as a 
benchmark. 
This project involves cellular anti-cancer drug screening, in vitro biological 
evaluation and mechanistic study of these novel kinase inhibitors in the early 
stages of the drug discovery process. 
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Chapter Two: Materials and Methods 
2.1 Materials 
MTTassay 
MIT Sigma-aldrich (cat: M2128-IG); DMSO Sigma-aldrich (cat: D5879-1L). 
Caspase 3 assay 
Sigma Caspase 3 Assay Kit, Fluorimetric cat: (CASP3F-IKT). 
p53 protein stabilization assay 
Reagents: Packard View 96-well microplates (Perkin-Elmer, cat: 6005182); 
Mouse anti-human p53 antiserum (Dako, cat: M700 I); Alexafluor 488 goat 
anti-mouse IgG secondary antibody (Invitrogen, cat: 449349); Bisbenzimide 
H33258, (Sigma, cat: B2883) 
Buffers and Solutions: PBST (137 mM NaCI, 2.7 mM KCI, 10 mM Sodium 
Phosphate dibasic, 2mM Potassium Phosphate monobasic, 0.1 % Tritonx 100, 
pH 7.4); Block buffer (PBST containing 1 % BSA); 50:50 v:v methanoVacetone 
stored at -20°C; Hoechst dye (lOmglml in water store at -20°C) 
Mitotic index assay 
Reagents: Cellomics Mitotic Index Kits (cat K0500011); Vinblastine (Sigma, 
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cat: V1377); Formaldehyde (37%) (Sigma, cat: 08779); Packard View 96-well 
microplates (Perkin-Elmer, cat: 6005182) 
Cell cycle analysis 
Reagents: Hypotonic Fluorochrome solution (0.1 % sodium citrate; 0.1 % Triton 
X-tOO; 50J,lg/ml propidium iodide; 100ug/ml RNAseA in dH20) 
Annexin V /PI staining assay 
Reagents: FITC Annexin V (BD Biosciences, cat: 556420); propidium iodide 
(Sigma, cat: P4170) 
Buffers and Solutions: 10)( binding buffer (0.1 M HEPES, Ph 7.4; 1.3 M NaCl; 
25 mM CaCh); propidium iodide solution (50 J,lg/ml in PBS). 
Western blot analysis 
Reagents: Precision Plus Protein WesternC Standards (Bio-Rad, cat: #161-
0376); Immun-Blot PVDF Membrane (Bio-Rad, cat: 9274011); Cassettes 
1.5mm (Invitrogen, cat: NC2015); Albumin (Sigma, cat: A4503); SuperBlock 
T20 Blocking Buffer (Thermo, cat:#37536); DC Protein Assay Reagent AlB/S 
(Bio-Rad, cat:500-01 13/0114/01 15); 30% Acrylamide solution (Severn 
Biotech, cat: 9352); complete Mini protease inhibitor cocktail tablet (Roche 
Diagnostics, cat: 11836153001); Amersham ™ ECL ™ Western Blotting 
Detection Reagents (GE Healthcare, cat: RPN2106); Amersham Hyperfilm ™ 
ECL High performance chemi-luminescence film (GE Healthcare, cat: 
28906837) 
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Buffers and Solutions: Resolving gel buffer (l.5M Tris.CI, pH 8.8, 0.4% SDS); 
Stacking gel buffer (lM Tris.CI, pH 6.8, 0.8% SDS); Resolving gel 7.5% / 
lOml (30% acrylamide 2.5 ml, resolving buffer 2.51 ml, dH20 4.99 ml); 
Resolving gel 10% /10 ml (30% acrylamide 3.33 ml, resolving buffer 2.51 ml, 
dH20 4.16 ml); Resolving gel 15% / 10 ml (30% acrylamide 5 ml, resolving 
buffer 2.51 ml, dH20 2.49 ml); Stacking gel 4% / 5 ml (30% acrylamide 
0.67ml, stacking buffer 0.63 ml, dH20 3.70 ml); Running buffer IL (3.03g 
Trizma Base, 14.4 g glycine, 1 g SDS); Transfer buffer 1 L (3.03 g Trizma Base, 
14.4 g glycine, 0.375 g SDS, 200 ml methanol); TBST 1L (6.6 g NaCI, 25ml 
1M Tris.CI pH7.5, 0.05% Tween 20); 4xLaenunii simple buffer 10 ml (2.4 ml 
1 M Tris pH 6.8, 0.8 g SDS stock, 4 ml 100% glycerol, 0.01 % bromophenol 
blue, 1 ml B-mercaptoethanol, 2.8 ml water); lysis buffer (5 mM HEPES pH 
7.5, 300 mM NaCI, 1.5 mM MgCh, 0.5% sodium deoxycholate, 20 mM p-
glycerophosphate, 1% Triton X-IOO, 0.1% sodium dodecyl sulfate (SDS), 0.2 
mM EDTA pH 8, 0.5 mM DTT, ImM sodium orthovanadate pH 10, 1 mM 
pheny1methylsulfonyl fluoride, 20 Ilg/mL aprotinin, and 20 Ilg/mL leupeptin); 
IOOml stripping buffer (0.76g Trizma base, 2g SDS and 0.7ml p-
mercaptoethanol). 
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Antibodies: 
Antibody Blocking buffer Dilution Storage Company Cat. 
RNAP II ser 2 5%BSA 1:500 -20°C Covance MMS-129R 
RNAP II ser 5 5%BSA 1:500 -20°C Covance MMS-134R 
Total RNAP II 5%BSA 1:500 _20°C Covance MMS-129R 
Mel-l 5%BSA 1:1000 _20°C Cell signaling #4572 
Bel-2 10% milk 1:1000 4°C Dako M0887 
XIAP 5%BSA 1 :1000 -20°C Cell signaling #2045 
p53 10% milk 1 :1000 4°C Dako M7001 
p21 5%BSA 1 :1000 -20°C Santa Cruz sc-397 
MDM2 10% milk 1:1000 -20°C Sigma M-7815 
PARP 10% milk 1:1000 _20°C Cell signaling #9542 
Cleaved PARP 10% milk 1:1000 _20°C Cell signaling #9546 
PPlu 5%BSA 1:1000 -20°C Cell signaling #2582 
Phospho-PP 1 u 5%BSA 1:1000 -20°C Cell signaling #2581 
Total Rb 5%BSA }:1000 -20°C Cell signaling #9309 
Rb (PT821) 5%BSA 1:1000 _20°C Invitrogen 44-5820 
y-H2AX 5%BSA 1:2000 4°C Millipore #05-636 
~ a c t i n n 10% milk 1:2000 _20°C Sigma A1978 
goat anti-mouse 1:4000 4°C Dako P0447 
swine anti-rabbit 1:4000 4°C Dako P0399 
Comet assay 
Reagents: CometAssay kit (Trevigen cat: 42S0-050-K). 
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RT-PCR 
Reagents: Oligo (dI)18 Primers (Bioline cat: Bio-38029); High resolution 
agarose (Invitrogen); RNeasl' mini kit (Qiagen cat: 74104); Iranscriptor 
Reverse Transcriptase (Roche cat: 03531317001); Taq DNA polymerase 
(Roche cat: 11146165001). 
Microarray 
Reagents: Human cot-l DNA (Invitrogen, cat: 15279-011); Cy5 mono-reactive 
dye pack (GE Healthcare, cat: PA25001); Cy3 mono-reactive dye pack (GE 
Healthcare, cat: P A2500 1 ); 
2.2 Methods 
2.2.1 Cell culture 
In a Class II microbiological safety cabinet, the cell culture techniques were 
performed before swabbing with 70% IMS in distilled water. MRC-5 and WI-
38 cell lines were cultured in minimum essential medium with 10% FBS, 1% 
of 7.5% Sodium bicarbonate, 1% O.lmM non-essential amino acids, 1% 1M 
Hepes, 1 % 200mM L-glutamine and 1 % penicillin. All other cell lines were 
maintained in RPMI-1640 with 10% FBS. The FBS was inactivated by heating 
(55 - 60° C) for 1 hour to denature complement proteins which would evoke 
cellular immune responses. All of the cells were incubated in a humidified 
incubator at 37° C with 5% CO2• Cells were sub-cultured when growth 
achieved approximately 80% confluence. During the sub-culture, the medium 
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was aspirated from the flask completely and 0.75 ml Ix trypsin-EDTA solution 
was added. The cells were put back to the incubator until most of them 
detached from the bottom of the flask, normally less than 5 minutes. The cells 
were re-suspended in lOml medium and 0.5-lml of the cell suspension was 
transferred to a new flask depending on the growth rate of the cells. The final 
medium volume in the new flask was adjusted to 10ml. In order to minimize 
the phenotypic drift, cells need to be discarded before passageing 40 times. For 
thawing cells, the cell vial was removed from liquid nitrogen storage and 
immersed into a 37° C water bath immediately. When the cells pulled away 
from the vial wall, the contents of the vial were transferred into a 25cm2 flask 
with 10mI pre-warmed medium. Two passages were needed to resume normal 
growth. For long-term storage, cells at approximately 80% confluence were 
detached by minimal trypsinlEDTA and suspended in freezing medium (FBS 
containing 5% DMSO), transferred to sterile cryogenic vials and kept at -20°C 
overnight followed by -80°C for 1-2 days and removed into liquid nitrogen 
storage. 
2.2.2 Compound solution 
Newly synthesized compounds were dissolved in DMSO to make up lOmM 
stock solutions. Flavopiridol stock solution was prepared in DMSO and the 
final concentration was I mM. All compound stock solutions were stored at -
20° C for up to 3 months. 
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2.2.3 MTT cell viability assay 
MIT (3-(4,S-Dimethylthiazol-2-yl)-2,S-diphenyltetrazolium bromide) is a 
yellow tetrazole which is reduced by mitochondrial dehydrogenases to 
insoluble purple formazan in living cells. DMSO is added to dissolve the 
insoluble purple formazan product into a coloured solution. The absorbance 
which reflects the amount of living cells can be quantified by measuring at a 
certain wavelength (usually between SOO and 600 om) by a spectrophotometer 
or plate reader. 
72h MIT assay: Dependent on different cell lines, IS00-3000 cells were added 
to each well from column 2 to 11 of each 96-well plate on the first day. The 
final volume was made up to 180111 with blank medium. 180111 medium was 
added to Columns 1 and 12 as blank controls. 2 columns of cells were plated in 
the To plate for each cell line. All plates were incubated at 37°C with 5% CO2 
overnight. In the morning of the second day, 5 0 ~ 1 1 MTT solution (2mg/ml in 
PBS phosphate buffered saline) was added to each well of the To plate. At the 
same time, compounds for test in 10mmol DMSO stock solution were diluted 
from ImM to 100nM with media. For each concentration, 20lll dilution was 
added per well in triplicate for each cell line resulting in a dilution range from 
I O O ~ ~ to IOnM. After 2-6 hours treatment in 37°C with 5% C02. all medium 
was removed from the To plate and 1 5 0 ~ 1 1 DMSO was added to each well. The 
To plate was analyzed after incubating in a shaker for 10 minutes. Absorbance 
of each well was quantified at 550 om using Perkin Elmer plate reader and the 
data was transferred to Microsoft Excel which was used to calculate the Olso 
value. Except for the To plate, all plates were incubated for 72 hours at 37°C 
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with 5% CO2. After 72 hours from drug addition, the plates were treated in the 
same way as the To plate on the second day. In 48h and 24h MTT assay, 2000-
4000 and 5000-8000 cells were added to each well on the first day depending 
on different cell types, respectively. Each assay was performed at least 2 times 
for candidate screening and at least 3 times for the mechanism studies of lead 
compounds. The mean value and standard deviation of each compound were 
calculated by Excel. 
2.2.4 Caspase activation assay 
2.2.4.1 Caspase-3 assay 
Caspase-3 activity was determined using the Sigma caspase-3 fluorimetric 
assay kit under the manufacturer's instructions. Briefly, 2x 104 HCT -116 cells 
were plated into each well in a 96 well plate and incubated at 37°C and 5% 
C02. After 24 hours, 10mM DMSO compound stocks were diluted to lOOIlM, 
20IlM, 51lM and 1 J.1M in a separate standard 96-well plate, then a multichannel 
pipette was used to transfer 20lll of diluted compound solutions to the cell 
assay plate which already contains 180lll of medium giving final 
concentrations of compounds of lOIlM, 21lM, 0.5 IlM and 0.1 IlM. Growth 
medium was used as blank and 0.5% DMSO in growth medium was used as 
negative control. Cell culture media was removed after compound treatment 
for 24 or 48 hours. Then, 25111 I xLysis Buffer was added to each well and the 
plate was incubated on ice for 15-20 minutes. After that, 200lli/well 1 xAssay 
Buffer containing substrate was added and mixed by pipetting. Finally, 
200llllwell of the solution was transferred to a fluorimeter multiwell plate and 
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the plate was read within 60 minutes. Activities were calculated using the 
AMC standard curve and each test was perfonned in triplicate. 
2.2.4.2 Caspase 3/7 activity assay 
Activity of caspase 3/7 was measured using the Apo-ONE Homogeneous 
Caspase 317 kit from Promega following the manufacturer's instructions. 
2.2.5 p53 stabilization assay 
HCT-116 cells were seeded at 1 x 104 cells/well in Packard ViewPlate black 
clear bottom 96-well microtitre plates. After 18h, cells were incubated with 
compounds with different concentrations (10!!M, 2!!M, 0.5!!M, O.I!!M and 
0.02!!M) for 7h at 37°C and 5% C02. At the end of treatment, Medium was 
removed and 100!!l/well cold 50:50 methanol: acetone (-20°C) was added for a 
3-min fixation at -20°C. The fixation solution was removed and the fixed cells 
were dried briefly, then washed once with 100!!lIwell PBST (PBS, 0.1 % triton 
X-I00) and incubated with 50!!1 primary antibody solution containing mouse 
anti-human p53 antiserum diluted 1:1000 in block buffer for 1 hour. After that, 
the primary antibody solution was removed and wells were washed 3 times 
with 100!!1 PBST. After incubation with 50!!1 secondary antibody and Hoechst 
dye solution containing Alexafluor 488 goat anti-mouse antibody (I :300) and 
Hoechst dye (l!!g/ml) for lh at room temperature in the dark, cells were 
washed 3 times with 100!!1 PBST and analyzed using a ImageXpressMICROTM 
automated fluorescent microscope (Molecular Devices). The percentages of 
cell nuclei stained with p53-specific antibody versus total cell nuclei stained 
with Hoechst were calculated automatically using Multi Wavelength Cell 
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Scoring application module. 
2.2.6 Mitotic index assay 
The assay was perfonned using the Cellomics Mitotic index kit from Thenno 
following the manufacturer's instructions. In brief, HCT-116 cells were seeded 
at 1 x 104 cells/well in Packard ViewPlate black clear bottom 96-well micro titre 
plates. After 18h, cells were incubated with compounds with different 
concentrations ( l O ~ , , 2J,lM, O.5J,lM, O.lJ,lM and O.02J,lM) for 7h at 37°C and 5% 
C02. After a 10-min fixation in lOOJ,ll of fixation solution at 37°C, cells were 
washed once with 100 .... ' / well of I x blocking buffer and penneabilized in 100 
J,ll of I x permeabilization buffer for 15 minutes. After washing, cells were 
incubated with 50J,lllwell primary antibody solution for I hour, and then with 
staining solution for another 1 hour. Finally, plates were sealed and evaluated 
on a ImageXpressMICROTM automated fluorescent microscope (Molecular 
Devices) to calculate the mitotic index which is the percentage of cell nuclei 
stained with the mitosis-specific antibody (anti-phospho-Histone H3) versus 
total cell nuclei stained with Hoechst. Vinblastine (O.S .... M) was used as a 
positive control and DMSO (0.2%) was used as a negative control. Assays 
were carried out using duplicate plates. 
2.2.7 Kinase assay 
Inhibition of CDKs and other kinases was measured by radiometric assay using 
the Millipore KinaseProfiler services. Half-maximal inhibition (lCso) values 
were calculated from 10-point dose-response curves and apparent inhibition 
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constants (Ki) were calculated from the ICso values and appropriate ATP values. 
2.2.8 Cell cycle analysis 
The analysis of cell cycle distribution was performed by flow cytometric 
measurement of cellular DNA contents. HCT-116, A2780 or MRC-5 cells were 
seeded at a density of 4x lOs/well in 6-well plates and incubated at 37°C, 5% 
CO2 overnight. Cells were treated with CDKI-71 or CDKI-83 at different 
concentrations and harvested with the medium at appropriate time points, 
washed with PBS (Phosphate Buffer Saline) (Sigma) and centrifuged at 
1200rpm for 5 minutes at 4°C. Supernatants were discarded and 300f.l1 
fluorochrome solution was added to each sample. Cells were suspended and 
transferred to F ACS tubes, protected from light and stored at 4°C overnight. 
Prior to flow cytometric analysis, the cell suspension was syringed using a 23g 
needle at least 3 times to obtain a single cell suspension. Fluorescence of PI 
stained nuclei was analyzed on a Beckman Coulter EPIS-XL MCL ™ flow 
cytometer and the data analysis was performed using EXP032 ™ software. 
2.2.9 Annexin V IPI staining assay 
HCT-116, A2780 or MRC-5 cells was seeded at a density of 4x lOs/well in 6-
well plates and incubated at 37°C, 5% C02 overnight. After the treatment with 
CDKI-71 or CDKI-83 at appropriate concentrations and time points, cells were 
collected in a F ACS tube, together with the culture media. The supernatants 
were discarded and the cells were re-suspended with Iml fresh media after 5-
min centrifuge at 1200rpm. Cells were counted and 1 x 105 cells were 
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transferred into a fresh F ACS tube with 1 ml PBS, and centrifuged at 1200rpm 
for another 5 minutes. Supernatants were discarded again and the cell pellet 
was re-suspended in 100fli binding buffer and 5 fll Annexin V-FITC. Samples 
were incubated at room temperature for 15 minutes in the dark and 400fll 
binding buffer was added, together with IOfll propidium iodide (50 flVml in 
PBS). Samples were kept on ice and protected from light for a further 10 
minutes and analyzed using FACS after vortex within Ih. 
2.2.10 Western blot analysis 
2.2.10.1 Preparation of cell lysate 
Cells were treated with compounds when the growth reached 50-70% confluent 
at 37°C with 5% C02 atmosphere. At appropriate time points, cells were 
collected and centrifuged at 1200rpm for 5 minutes, 4°C. The pellet was 
washed with PBS and re-suspended in lysis buffer which contained a complete 
Mini protease inhibitor cocktail tablet in every 10mI. Cell lysates were stored 
at _20° C until use. After thawing, the lysates were centrifuged (l2000rpm, 4°C, 
10min) to remove insoluble proteins and cell debris before protein analysis. 
2.2.10.2 Protein assay 
Protein concentrations in celllysates were determined using DC Protein Assay 
Reagents AIBIS following the manufacturer's instructions. 
2.2.10.3 SDS PAGE 
SDS PAGE was used to separate protein mixtures based on their molecular 
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mass by passing them electrophoretically through a polyacrylamide gel. 
Depending on the molecular mass of the protein of interest, different 
concentrations of acrylamide were used in the gels (7.5-15%). Polymerisation 
was initiated after the addition of APS and TEMED in a gel cassette. Stacking 
gel buffer with APS and TEMED was added after the resolving gel had 
polymerised. A comb was added immediately to create sample wells. 
Cell lysate samples with loading buffer, each containing 50-200llg proteins 
depending on cell lines, were denatured at 9SoC for S minutes. Each sample 
was then loaded into a well in the stacking gel. Sill Precision Plus Protein 
WestemC Standards were added to the first well. Protein samples were 
separated by SDS-P AGE at a voltage between 60-150V using running buffer. 
After electrophoresis, gels were removed from cassettes and prepared for 
electro-transfer onto a PVDF membrane. 
2.2.10.4 Immunoblotting 
Proteins separated by SDS-P AGE in gels were electro-transferred onto PVDF 
membranes using transfer buffer (25V overnight). Membranes were blocked in 
TBST with either 5-10% BSA or 10% dried non-fat milk (dependant on 
primary antibodies) for Ih at room temperature with gentle shaking, followed 
by incubation with primary antibody solutions overnight at 4°C. To remove 
excess unbound primary antibodies, membranes were washed with TBST 3 
times, 5-10min each. Incubation with appropriate secondary antibodies 
conjugated to horseradish peroxidise for Ih was followed at room temperature. 
Membranes were rinsed again before visualisation using ECL system. 
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2.2.10.5 Enhanced chemiluminescence (EeL) reaction 
Following the procedures in the manufacturer's instruction of Amersham™ 
ECL™ Western Blotting Detection Reagents, membranes were exposed to 
high performance chemiluminescence films in the dark for appropriate 
exposure times. Films were developed manually. 
2.2.10.6 Membrane stripping 
Membranes were incubated with stripping buffer for 30 minutes at 50°C, 
followed by rinsing under running water for lh and 3x 10min with TBST. 
2.2.11y-H2AX foci 
Cells were seeded at 1 x 104 cells/well in Packard ViewPlate black clear bottom 
96-well microtitre plates and incubated overnight at 37°C and 5% C02. Cells 
were treated with 0.2J.1M flavopiridol or 5J.1M CDKI-71 for 6h, the medium 
was removed and 100J.1l/well cold 50:50 methanol: acetone (-20°C) was added 
for a 5-min fixation at -20°C. The fixation solution was removed and the fixed 
cells were washed once with IOOlli/well cold PBS and incubated with 
permeabilization buffer for 15 mins at room temperature. After washing and 
incubating with blocking buffer, cells were incubated with mouse monoclonal 
anti-y-H2AX (Ser 139) at 1:1000 dilutions in blocking buffer for Ih at room 
temperature. Cells were then washed 3 times with blocking buffer and then 
incubated with Alexafluor 488 goat anti-mouse secondary antibody (Molecular 
Probes) at a dilution of 1:1000 and Hoechst dye (lJ.1g1ml) in blocking buffer for 
Ih at room temperature in the dark, followed by washing with PBS. Images 
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were taken through a ImageXpressM1C'ROTM automated fluorescent microscope 
(Molecular Devices). Cisplatin (5J.lM) was used as a positive control and 
DMSO (0.2%) was used as a negative control. Assays were carried out in 
duplicate plates. 
2.2.12 Comet assay 
The comet assay or single cell gel electrophoresis assay is used to detect DNA 
damage in individual cells. The assay is based on the ability of denatured or 
cleaved DNA fragments to migrate out of the cell under an electric field, 
whereas undamaged DNA migrates slower and remains within the nucleoid 
under electrophoresis. 
The comet assay was performed using the Trevigen CometAssay kit under 
alkaline conditions, following the manufacturer's instruction. After treatment, 
MRC-5 cells at I x 105 Iml were combined with molten LMAgarose (37°C) at a 
ratio of 1:10 (v/v) and 50J.lM was added onto each Cometslide. After 20 
minutes, slides were immersed in cold lysis solution at 4°C for 30 minutes. 
Then, excess buffer was removed and slides were incubated in freshly prepared 
Alkaline Solution for 20 minutes at room temperature, in the dark. 
Electrophoresis was performed for 40 minutes (1 volt/em, current about 
300mA) in alkaline electrophoresis solution (ImM EDTA and 300mM NaOH, 
pH > 13). All steps beginning with the cell lysis were conducted under dim 
light to prevent additional DNA damage. Samples were washed with distilled 
water and 70% ethanol and dried at 40°C for 15 minutes. Onto each circle of 
dried agarose, lOO1l1 of diluted SYBR Green I nucleic acid gel stain was added. 
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Nikon Eclipse TS 1 00 fluorescence microscopy equipped with fluorescein filter 
and camera was used to record images. Analysis was performed using the 
Comet Assay IV program. Typically, 50 cells were analyzed per slide with two 
slides for each treatment. 
2.2.13 Reverse Transcription polymerase chain reaction (RT-
peR) 
This experiment was performed with the help of Dr Frankie Lam. 
2.2.13.1 RNA preparation and quantification 
A2780 cells were treated with COKI-83 when the growth reached 50-70% 
confluence at 3rC with 5% C02 atmosphere. At appropriate time points, cells 
were collected and RNA was extracted using RNeasy® mini kit according to 
the manufacturer's instruction. The concentrations of RNA samples were 
determined by a NanoOrop® NO-lOOO spectrophotometer (Thermo Fisher 
Scientific). 
2.2.13.2 Reverse transcription and peR 
Reverse transcription and PCR were performed according to the standard 
operating procedures provided by Roche. Oligo (dT) 18 primers were provided 
by Bioline. Reverse transcriptase and PCR grade nucleotide mix were obtained 
from Roche. The primers for amplifying J3-actin were purchased from MGW 
Biotech AG and the primers for Mcl-l and Bcl-2 were designed by Dr Scott 
Roberts and produced by Sigma. The designed primers for Mcl-l were 
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5'GAAGGCGCTGGAGACCTTAC3' (forward) and 
5 'CATTCCTGATGCCACCTCT3 , (reverse). For Bcl-2, the primers were 
5'ATGTGTGTGGAGAGCGTCAA3' (forward) and 
5'GCCGTACAGTTCCACAAAGG3' (reverse). 
2.2.13.3 Agarose gel electrophoresis and visualization of bands 
Agarose gel (2.5%) was prepared in TBE buffer (O.89M Trizma base, 0.02M 
EDTA, 0.89M Boric acid) and heated by microwave to dissolve the agarose. 
The gel was cooled down to around 60° C and ethidium bromide (EtBr) was 
added to a concentration of 0.2f.J.g/ml. The mixture was poured into a gel plate 
with casting combs inserted. After the gel was set, the combs were removed 
and 5f.J.l PCR product was loaded to each well with If.J.lloading buffer. Samples 
were separated by electrophoresis at tOOV for lh and visualised under UV. 
Images were recorded digitally using a Benchtop 3 UV ™ Transilluminator 
(UVP). 
2.2.14 Microarray 
A2780 cells were treated with CDKI-7t (If.J.M) or flavopiridol (0.2f.J.M) for 6 
hours. After treatment, RNA samples were prepared and quantified as 
described in 2.2.13.1. The 30,000 gene probe pan human Array (MWG Biotech) 
slides were purchased from Genomics Facility, QMC, University of 
Nottingham. Reverse transcription, cDNA purification, probes labelling and 
hybridization were performed by Miss Adeline Barthet-Barateig. The arrays 
were scanned on an Axon Genepix 4000b scanner and quantified using 
Genepix Pro 6. For each gene, a log2 ratio was calculated automatically 
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between its treatment and control intensities. The features with high 
background or which were significantly unifonn were removed from analysis. 
Then the R program with the "Limma" package was used to analyze expression 
of the microarray data and the 158 probe sets whose expression changes more 
than 1 log (llog21> 1) by CDKI-71 treatment were chosen for further analysis. 
Hierarchical clustering was performed and visualized using MeV version 4.6.2 
for the 158 probe sets. The web-based Database for Annotation, Visualizaton 
and Intergrated Discovery (DA VID) was used for functional annotation. 
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Chapter Three: Screening and classification 
of an inhibitor compound library 
3.1 Introduction 
Because of similarities in structure of kinases, particular in the A TP-binding 
motif among all protein kinases, target specificity is the main problem in the 
development of A TP-antagonistic inhibitors. Furthermore, identify the primary 
target of designed anti-cancer kinase inhibitors in cancer cells plays a key role 
in kinase drug development. 
Hundreds of compounds designed to target diverse kinases have been 
synthesized by our group. These include CDK9 inhibitors (S-, S2-, S3-, SW-, 
D- and E-series), CDK7 inhibitors (coded PL4-series) and Polo-like kinase 1 
(Plkl) inhibitors (OC-series). A cell-based screening cascade was developed to 
classify compounds and identify effective transcription CDK (CDK7 and 
especially CDK9) inhibitors as lead candidates. 
This screening cascade comprised an MIT assay, a Caspase-3 activation assay, 
a p53 stabilization assay and a mitotic index assay. SW-32, a potent CDK9 
inhibitor (Wang et aI., 2004), was used as a positive control. 5,6-Cichloro-l-
beta-d- ribofuranosylbenzimidazole (DRB), the most selective CDK9 inhibitor 
known (Wang and Fischer, 2008), was used as a further positive control in this 
screening cascade. 
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3.2 Results and Discussion 
3.2.1 Cell viability 
Effective anti-cancer drugs normally induce cancer cell death or inhibit 
proliferative activity, both of which decrease cancer cell viability. MTT is a 
water soluble yellow dye which can be converted to insoluble purple crystal 
formazan by mitochondrial dehydrogenases in viable cells. At the first stage of 
the screening cascade, the anti-proliferative activity of more than 100 new 
synthesized compounds was tested using 72h-MTT assay on HCT -116 cells. 
Compounds with G1so values below IJ.lM are summarized in Figure 3.1. A 
number of compounds including 8W-32, 8W-130, 8W-118, 83-41, 83-53, S2-
123, 82-122, S2-104, 8-134, 8-64 and OC-21 showed potent anti-proliferative 
activity with Glso values below 100 nM. In similar experiments, DRB has 
modest cytotoxicity with a G1so value of 32.86 ± 6.85J.lM. 
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Figure 3_1 GISO values of 46 compounds in HCT-116 cells (MTT assay)_ HCT-11 6 cells 
were treated with different compounds for 72 hours_ Horizontal bars represent the mean Gl so 
values ± SD of at least two independent experiments 
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3.2.2 Activation of caspase-3 
As discussed in Chapter one caspases are a family of proteases of which at 
least seven (caspases 2, 3,6, 7, 8, 9 and 10) contribute to cell death (Kroemer 
and Martin, 2005). The most studied caspase, caspase-3 is known to be 
activated in apoptotic cells by both intrinsic and extrinsic pathways and 
expression of activated caspase-3 is a marker of apoptosis (Konstantinidou et 
aI., 2007). 
The caspase-3 substrate acetyl-Asp-Glu-Val-Asp-7 -amido-4-methylcoumarin 
(Ac-DEVD-AMC) is hydrolyzed by caspase-3, resulting in the release of the 
fluorescent 7-amino-4-methylcoumarin (AMC) moiety. The excitation and 
emission wavelengths of AMC are 360 nm and 460 nm, respectively. Through 
measuring the fluorescent intensity, the activity of caspase-3 can be quantified. 
Caspase 3 
Ac-DEVD-AMC ~ ~Ac-DEVD + AMC 
Transcription CDK9 inhibitors were reported to down-regulate anti-apoptotic 
proteins and induce apoptosis in a caspase dependent manner (Liu et a1.; Smith 
et aI., 2008). Induction of caspase-3 and apoptosis were also detected after a 
treatment with a clinical Plkl inhibitor ON01910 (Gumireddy et aI., 2005). 
Therefore, the ability of inhibitors to induce apoptosis can be predicted by 
screening the induction of caspase-3. 
The caspase-3 activity after treatment was determined for compounds with Olso 
values below IJ.l.M. Figure 3.2 shows the induction of caspase-3 in HCT-116 
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cells after treatment with 46 compounds for 24 or 48 hours. ORB was used as a 
positive control in this experiment. As shown in Figure 3.2, 48h treatment 
induced higher caspase-3 activity for the majority of compounds. Based on the 
results of 48h treatments, the 46 compounds were classified into 3 groups: 
Group 1: Compounds induced caspase-3 activities at concentrations::: O.S .... M 
(OC-21, S3-53, S3-71, S3-41, SW-32, SW-II8, S-134, OC-22, S-62, S3-36, 
S2-67, E-24, E-29 and S2-106). 
Group 2: Compounds induced caspase-3 activities at concentrations between 
2 .... M and IO .... M (S-64, S2-123, S3-49, OC-20, OC-IOO, S2-103, S2-124, S2-69, 
0-22, SW-26, SW-137, S3-50, SW-47, PL4-39, OC-24, S3-48, 0-30, S-130, 
0-29, S3-47, PL4-40, SW-134, S-66, SW-34, OC1IO and SW-117) 
Group 3: Compounds do not induce caspase-3 activities (SW-130, S2-122, S-
139, S2-125 and SW-19). 
As a lead compound, SW-32 induced caspase-3 activity at a very low 
concentration (O.I .... M). This is consistent with its G1so value obtained in the 
MIT assay. However, SW-32 treatment at higher concentrations did not 
increase the level of caspase-3 activity. This also occurred with other inhibitors, 
such as E-24, S3-36, and S3-53. Since these compounds were very cytotoxic, at 
the higher concentrations they induced significant cell death. This may be the 
reason why induction of caspase-3 has not been detected. As shown in Figure 
3.2 ORB induced caspase-3 activity significantly at 50 .... M, which is similar to 
its GIso value in the MIT assay (32.86 .... M), indicating the anti-proliferative 
effect of ORB is mainly due to the induction of apoptosis. 
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Figure 3.2 Induction ofCaspase-3 activities in HCT-1l6 cells. HCT-116 cells were treated 
with different compounds for 24 or 48 hours. Vertical bars represent the means ± SD of at least 
2 independent experiments. 
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The concentration at which caspase-3 activity was induced was compared with 
the 0150 value of each compound. The majority of compounds induced 
caspase-3 activity at higher concentrations than the allocated 0150 values, 
indicating higher concentrations were needed to trigger apoptosis. However, 10 
compounds (SW-32, ORB, S3-71, S3-41, OC-22, S-62, S3-36, S2-67, E-24 
and S2-106) showed similar concentrations, including both positive controls. 
The 0150 values obtained from MTT assay only reflects the anti-proliferative 
effect of the tested compounds. Both cytostatic and cytotoxic compounds can 
stop or slow down the cells growth, but only cytotoxic compounds kill them. A 
review published recently summarized the relationship between caspase 
dependency and cell death morphotype (Kroemer and Martin, 2005). Caspase 
activation not only occurred with apoptotic cell death (apoptosis), but also with 
some nonapoptotic cell death, including apoptosis-like cell death, autophagic 
cell death and necrosis. However, apoptosis cannot occur without activation of 
caspase. Many CDK9 inhibitors such as flavopiridol (Oojo et at., 2002), 
Seliciclib (MacCallum et at., 2005), and SNS-032 (Chen et aI., 2009) were 
reported to induce cancer cell apoptosis through activation of caspase pathway 
Therefore, detection of caspase induction would provide us another method for 
screening of potent COK9 inhibitors. 
The compounds that do not induce caspase-3 activity, including SW-130, S2-
122, S-139, S2-125 and SW-19, are more likely to target other cellular targets 
other than or in addition to CDK9. However, induction of caspase is highly 
dependent on the amount of cells. If compounds tested are extremely toxic and 
kill the cells in a short time, no caspase induction would be detected. Therefore, 
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further tests might be worth to perform for the compounds which kill the cells 
immediately without caspase induction. Targeting other kinases, for example 
cell cycle kinases, may inhibit cell proliferation while CDK9 inhibition induces 
apoptosis through caspase activation. Thus, compounds S3-71, S3-41, OC-22, 
S-62, S3-36, S2-67, E-24 and S2-106, with similar 0150 values and Caspase 
induction concentrations, have the largest potential to be selective CDK9 
inhibitors. 
3.2.3 Induction of p53 protein 
CDK9 inhibitors were reported to reduce the expression of MDM2, a well-
established negative regulator of p53, resulting in p53 stabilization (Alonso et 
aI., 2003; Demidenko and Blagosklonny, 2004; Liu et aI., 2011 b) . Induction of 
p53 protein levels has been considered a marker ofCDK7/9 inhibition (Shapiro, 
2006) and detection of nuclear p53 protein accumulation was used to screen 
and identify transcription CDK7/9 inhibitors (Wang et aI., 2010). 
In order to identify potent CDK9 inhibitors, the effects of the 46 compounds 
with 0150 values below l).1M on p53 protein were further assessed using a 
relevant high-throughput automated microscopy system. Nuclear accumulation 
ofpS3 was assessed by immunofluorescent staining and the percentage of cells 
with p53 positive nuclei versus total cell nuclei stained with Hoechst was 
calculated. 
Based on previous data (Wang et aI., 2010), 7h treatment was chosen to 
identify the maximum effects on induction of pS3 protein levels. 
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Figure 3.3 illustrates the response of HCT -116 cells p53 levels after treatment 
with each compound, the 46 test compounds falling into 3 groups: 
Group 1: Compounds induced p53 at concentrations ~ ~ 0 . 5 ~ M M (SW -130, OC-21, 
S3-53, S2-104, S3-71, S3-41, SW-32, S-62, S2-67, E-24 and E-29). 
Group 2: Compounds induced p53 at concentrations between 2 ~ M M and 10J,lM 
(8-64, 8W-1l8, 8-134, 83-36, OC-20, 82-103, 82-124, 82-69, 0-22, S2-125, 
8W-19, 8W-137, 8W-47, OC-24, S2-106, 83-48, 0-30, S-130, 0-29, S3-47, 
PIA-40, 8W-134, 8-66 and 8W-34). 
78 
Percentage(") of ce lis with p53 p o s ~ i v e e nuclei 
100 
o 1 0 u ~ ~
. 2uM 
90 D O.5uM 
80 Co. JuM 
. 0.02uM 
70 OOM50 
60 
50 
40 
30 
20 
10 
0 
SW-J2 SW-117 SW- IIS SW-BO SW-1l4 SW-ll1 52 - 106 SJ-J5 53-36 5)-4 1 
Percentage(") of cells w ith pS3 positive nuclei 
o 1 0 u ~ ~
90 
. 2uM 
80 0 0. 6 u ~ ~
OO.luM 
70 
. 0.02ulll 
60 OOM50 
50 
40 
30 
20 
10 
0 
52·103 52·104 52·122 52·1l.} 52·12. 52·m 53-47 53 .. ' 53 .. 9 53·50 
Percentage(") of cells w ith p53 p o s ~ l V e e nuclei 
90 OIOuM 
. 2uM 
80 0 0. 5uM 
70 OO.luM 
. 0.02uM 
60 o O ~ S O O
50 
40 
30 
20 
10 
0 
022 029 0 30 562 564 S66 SWI9 SW26 SWJ4 SW'7 
79 
P ~ = n t a l l ~ ~ " ) o f c e l l l w i t h h p53 p o o i t i i ~ ~ nuclei 
90 
80 
70 
60 
50 
40 
30 
20 
10 
o ~ ~ .r 
OC·20 OC·21 OC·22 E·24 
P ~ = n t a l l ~ ~ " ) ) of cells with p53 p o s i t i v ~ ~ n u d ~ i i
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
0 
PIA·39 P1A-40 
Il 
~ ~ ~ ~
E·29 S·130 1).134 S·139 
53·S3 OC24 OCIOO 
S2-61 S2-69 
OCIIO 
o 10uM 
2uM • 
0 
0 
-c 
O. 5 5 ~ ~
O. l u ~ ~
O.02uM 
DMSO 
O IOuM 
- 2uM 
0 0. SuM 
OO. luM 
. 0.02u\l 
DDMSO 
Figure 3.3 p53 protein levels in HCT-1l6 cells after treatments. HCT-116 cells were treated 
with different compounds for 7 hours. Vertical bars repre ent the means ± SD of at least 2 
independent experiments. 
Group 3: Compounds do not induce p53 (S2-122, S2-123, OC-22, S3-49, 
OCIOO, S-139, SW-26, S3-50, PJA-39, OCI10 and SW-117). 
It can be seen clearly that SW-32, as a lead compound and positive control, 
increased p53 level at 0.1 ~ M M which is the same concentration required to 
induce caspase-3 activity. It also has been reported that DRB induced p53 by 
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down-regulation of Mdm-2 (Blagosklonny et aI., 2002) and 30llM DRB can 
induce p53 level significantly (Lam, 2010). In the previous caspase-3 study, 
DRB was found to induce caspase-3 at 50 11M, similar to its GIso (32.86IlM). 
Therefore, similar activation concentrations were observed from these 3 assays 
for both of the CDK9 inhibitor positive controls (SW -32 and DRB). 
3.2.4 Summary 
More than 100 compounds were tested via the screening cascade and the 
results are summarized in Table 3.1. Based on the property of known CDK9 
inhibitors, the following criteria were used for candidate compound selection: 
• High potency in an anti-proliferative assay - candidates should inhibit 
the cell growth at a nano-molar level. Although more than 100 new 
synthesized compounds were tested in HCT -116 using MTT assay, only 
46 compounds with GIso values below I J-lM were selected for further 
assays (Table 3.1). 
• Effective induction of both caspase-3 and p53. Compounds S2-122 and 
S-139 had no effects on either, while 14 compounds only affected either 
caspase-3 activity or p53 protein level. Therefore, these 16 compounds 
have less potential to be potent CDK9 inhibitors (Table 3.1). 
• Comparative potency cross all three assays. Compounds S3-41, S2-67, 
E-24, E-29, S3-71 and S-62, designed for inhibition of CDK9, and 
compound OC-21, designed as a Plk-l inhibitor followed this rule. 
Each of them inhibited cell growth, induced caspase-3 activity and 
increased p53 protein level at similar concentration (Table 3.1). 
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Table 3.1 Summary of MTT, caspase-3 activity and p53 stabilization assays. 
Cell-based assays, (11M) 
Compounds MTIGIso• Caspase 3 activity # p53 stabilization# candidate 
OC-21 0.01 0.1 0.02 >f 
S3-41 0.04 0.1 0.1 >f 
SW-32 0.04 0.1 0.1 control 
82-67 0.25 0.5 0.5 >f 
E-24 0.32 0.5 0.5 >f 
E-29 0.39 0.5 0.5 >f 
S3-71 0.40 0.5 0.5 J 
8-62 0.20 0.5 0.5 J 
S3-53 0.03 0.5 0.5 
SW-118 0.05 0.5 2 
S-134 0.06 0.5 10 
S3-36 0.20 0.5 2 
S2-106 0.59 0.5 10 
S-64 om 2 2 
S2-104 0.03 2 0.5 
OC-20 0.32 2 10 
S2-103 0.40 2 2 
S2-69 0.49 2 2 
0-22 0.52 2 2 
SW-137 0.55 2 2 
SW-47 0.57 2 10 
OC-24 0.59 2 2 
D-30 0.62 2 10 
S-130 0.69 2 10llM 
D-29 0.71 211M 2J.lM 
PL4-40 0.75 2J.lM 211M 
S-66 0.81 211M 211M 
SW-34 0.83 211M 10 11M 
S2-124 0.48 1OJ.lM 2J.lM 
S3-48 0.60 10llM 10llM 
S3-47 0.72 IOIlM lOIlM 
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SW-134 0.78 IOIlM 
OC-22 0.16 0.51lM 
S3-49 0.30 21lM 
OClOO 0.35 21lM 
S3-50 0.56 21lM 
PL4-39 0.59 21lM 
OCllO 0.85 21lM 
SW-ll7 0.89 21lM 
S2-123 0.08 10ilM 
SW-26 0.55 IOIlM 
SW-130 <0.01 
S2-125 0.53 
SW-19 0.54 
S2-122 0.06 
S-139 0.53 
*: 72 hours MTT assay 
#: the concentration at which the activity was significantly induced 
I: no effects even at the highest concentration 
3.2.3 Cell cycle effects 
As described previously, CDK9 regulates transcription. Reduction of CDK9 
level by siRNA had no appreciable effects on cell cycle distribution (Cai et aI., 
2006b). Apoptosis was detected after treatment with a selective CDK9 
inhibitor from all stages of the cell cycle (Wang et aI., 2010), while SW-32, a 
potent inhibitor of CDK9 and CDK2 was reported to reduce mitotic index 
(Wang et aI., 2004). In contrast, inhibition of Plkl resulted in spindle 
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abnonnalities and mitotic arrest followed by apoptosis (Gumireddy et aI., 2005; 
Sumara et aI., 2004). 
To distinguish the transcriptional CDK inhibitor compounds from Plkl 
inhibitors, a mitotic index assay was introduced. Mitotic index is the ratio 
between the number of cells in mitosis and the total number of cells. It's a 
valuable means of characterizing cell proliferation, and represents the cell 
fraction within a population undergoing cell division. In this study, HCT-116 
cells were treated with selected inhibitor compounds for a period of 7 hours 
and the mitotic index was measured. Vincristine, which is known to target 
tubulin dimers and the capable of arresting cells in mitosis, was used as a 
positive control, and DMSO vehicle as a negative control. The mitotic index 
was calculated by measuring cell nuclei stained with the positive mitosis-
specific antibody (anti-phospho-Histone H3) versus total cell nuclei stained 
with Hoechst. ORB was used as CDK9 inhibitor control. Compounds selected 
for the assay were E-29, S2-122, S3-71 and S3-41 which are designed to target 
CDK, while OC21, OCtoO and OCII0 are potential mitotic inhibitors. 
As shown in Figure 3.4, compound series OC21, OCtoO and OCIIO increased 
mitotic index at 10 J.l.M, which is consistent with the effect of plkl inhibitor 
ON01910 (Gumireddy et al., 2005). CDK9 inhibitor E-29 decreased mitotic 
index significantly at 2 J.l.M, which is similar to the COK9 positive control 
ORB at 50 J.l.M. S3-71 also decreased mitotic index, but with less significance, 
while S3-41 showed no effects on the mitotic index. 
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Figure 3.4 Cell cycle status detected by mitotic index. HCT -117 cells were treated with 
compounds with a range of concentrations for 7 hours. Vertical bars represent the means ± SO 
of at least 2 independent experiments. 
The kinase inhibition activites of compounds E-29, S2-122, S3-71 , S3-41 and 
ORB were tested at 1 11M for 6 COKs and the Ki values against COK9 were 
obtained (Table 3.2). Candidates S3-41 , S3-71 and E-29 inhibited CDK9 and 
CDK2 potently and the Ki values for CDK9 were 6, 6 and 27 nM, respectively, 
indicating the efficacy of our screening cascade. Through the compound 
screening, S2-122 was not selected as a CDK9 inhibitor candidate because it 
failed to induce caspase-3 and p53 . Kinase assay shows S2-122 had no activity 
against CDK9 and other COKs, further confmning the practicality of the 
screening cascasde. 
CDK2 binds to CyclinE or CyclinA, regulating G 1 /S transition and S phase 
progress (Knockaert et aI., 2002). However, recent studies show a variety of 
cancer cell lines are able to proliferate after specific and acute depletion of 
CDK2, suggesting CDK2 inhibition may not be useful therapeutically (Ortega 
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et aI., 2003). In addition, the primary target of flavopiridol and SNS-032, 
which are pan CDK inhibitors, are believed to be through CDK9 inhibition in 
chronic lymphocytic leukemia (Chen et aI., 2005; Chen et aI., 2009). Therefore, 
CDK9 inhibition may playa key role in the cytotoxicity of the compounds in 
cancer cells. 
Table 3.1 Inhibition ofCDKs by kinase assay· 
CDK1I8 CDK2/A CDK4/D CDK5/p25 CDK7/H CDK9rr CDK9rr** 
S3-41 89 98 51 83 45 96 6 
S3-71 94 99 92 95 80 99 6 
E-19 66 89 22 54 58 92 27 
DRB o o o o 10 64 304 
Sl-11l o o o o o o >10 
• Percentages of inhibition at 111M against 6 CDKs were obtained. Half-maximal inhibition 
(ICso) values for CDK9 were calculated from IO-point dose-response curves ... K; in nM 
represented by the means of two independent measurements. 
3.3 Conclusion 
More than 100 new synthesized compounds were tested by MIT assay and 46 
compounds were further screened using caspase-3 activation assay and p53 
stabilization assay to identify potent CDK9 inhibitors. The cell cycle effects 
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were detected by mitotic index assay. Based on the above results, compounds 
S3-41, S2-67, E-24, E-29, S3-71 and S-62 were chosen as key CDK9 inhibitors. 
Compounds S3-41 and S3-71 are the most potent CDK9 inhibitors identified. 
They have potent anti-proliferative activity; induce both caspase-3 activity and 
p53 protein level, which are the cellular marker of CDK9 inhibition. Most 
importantly, these two compounds showed comparative potency across all the 
three assays in our screening cascade without significant effects on mitotic 
index, suggesting their anti-proliferative effect would be due to CDK9 
inhibition . 
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Chapter Four: Cellular mechanism of action 
of a novel CDK9 inhibitor CDKI-71 
4.1 Structure and kinase activity 
Through our screening assays, CDKI-71 (S3-71) was chosen as a lead CDK9 
inhibitor. The cellular effects of CDKI-71 were compared with the clinic 
compound flavopridol to verify the mechanism of action (Liu et aI., 2011 b). 
The structures and CDK inhibitory activity of CDKI-71 and flavopiridol are 
summarized in Table 4.1. The CDK inhibitory activity was measured by 
mdiometric assay from Millipore. Similar activities were determined for 
CDKI-71 and flavopiridol against CDK9, CDK7, CDK1 and CDK6, with the 
highest potency being against CDK9 (Ki = 6 and 3 nM for CDKI-71 and 
flavopiridol respectively). However, CDKI-71 is more potent against CDK2 
(Ki = 4 nM) than flavopiridol (Ki = 79 nM). 
Table 4.1 Chemlnl structures and summary ofCDK Inhibitory activity. 
HN- OH 0 
N ~ ~ ~ ~;'(:;.. M / N ~ ~
N N ~ ~ O OH 0' 
HO 
CDKI-71 flavplridol 
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Compounds 
Flavopiridol 
CDKI-71 
Kinase inhibition, Ki (nM) 
CDK9ffl CDK7/H CDKIIB CDK2/E CD KS/pS3 CDK61D3 
3 
6 
113 
114 
13 
12 
79 
4 
100 
920 
265 
205 
Inhibition of CDKs was measured by radiometric assay using the Millipore KinaseProfiler 
services. Apparent inhibition constants (Ki) were calculated from ICso values and the 
appropriate Km (ATP) values for each kinase (Cheng Y, 1973). 
4.2 Growth inhibition effect 
CDKI-71 and flavopiridol were widely tested using 48h MTT anti-proliferation 
assay on a panel of 12 tumour cell lines and two normal human diploid 
fibroblast cell lines. The half-maximal growth inhibition (Olso) values are 
summarized in Table 4.2. Tumour cell lines from different origins were 
introduced, such as colon, breast, renal, ovarian, pancreatic and cervical. To 
investigate whether the cell growth inhibition effect is p53 or Rb dependent, 
cell lines with different p53 and Rb status were also included in our cell panel 
(Table 4.2). MRC-5 and WI-38 cells are well characterized normal diploid 
fibroblasts and are the most commonly used non-cancerous cell lines (Jacobs et 
a1.,1970). 
Flavopiridol was reported to induce cancer cell apoptosis in a p53 and Rb 
independent manner (Alonso et aI., 2003). In our MIT assay, both compounds 
show similar sensitivity for cells with different p53 and Rb status, indicating 
p53 and Rb independent anti-proliferative activity. CDKI-71 suppressed 
tumour cell growth with similar Olso values ranging from 287 to 854 oM in 
89 
different tumour cells, but was about lO-fold less potent than flavopiridol in the 
same cell lines. However, MRC-5 and WI-38 cells were significantly less 
sensitive to CDKI-71 (GI5o = 4277 and 2265 oM, respectively), showing the 
tumour cell selective effect of CDKI-71. In contrast, all cell lines were 
sensitive to flavopiridol, irrespective of cell type (tumour or non-transformed). 
The tumour cell specific cytotoxicity ofCDKl-71 was also observed in patient-
derived CLL cells, as well as normal B- and T-cells, by Annexin V-FITC 
apoptosis assay carried out by Dr Chris Pepper. CDKI-71 showed its potency 
with LDso = 0.43 JiM against CLL cells, while little effect was observed in 
normal B- and T -cells (LDso > 500 and > 700 IlM, respectively). In contrast, 
flavopiridol exhibited similar toxicity in the three cell lines (LD5o = 0.34, 0.59 
and 0.81 JiM, respectively). 
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Table 4.2 Average Glso values (nmoIlL) for CDKI-711flavopiridol-mediated growth 
inhibition in a panel of human c:eIlUnes. 
Human cell line Glso nmollL ± SO 8 
Origin Designation COKI-71 Flavopiridol 
HCT-116 (p53+1+) 472±25 46±4 
Colon 
HCT-116 (P53-1-) 484±14 54±1 
Melanoma MDA-MB435(Rb+)(P53 mutant) 553±111 81±7 
MOA-MB468(Rb-)(P53 mutant) 512±9 70±18 
Breast 
MCF-7 (p53 wild type) 483±32 41±7 
TKIO 769±158 48±4 
Renal 
CAKI-I 589±2 I 64±5 
IGROV-I 854±168 59±12 
Ovarian A2780 287±3 21±5 
SKOV-3 752±118 73±6 
Pancreatic Miapaca-2 650±16 78±7 
Cervical Hela 446±37 43±1 
Embryonic Lung WI-38 2265±744 77±20 
Fibroblast MRC-5 4277±761 49±9 
": Average values ± SD from three independent deterrmnahons 
To fmd out the effect of treatment time on CDKI-71 anti-proliferative activity 
time-course MIT assays were perfonned using HCT -116, A2780 and MRC-5 
for 24, 48 and 72h (Figure 4.1). Treatment for 24h was almost sufficient to 
achieve the highest growth inhibition for CDKI -71. Cell numbers decreased 
sharply between 0.1 J.lM and 1 J.lM treatment for all time points in HCT -116 and 
A2780 cancer cells. However, proliferation inhibition occurred only at lOf.1M 
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treatment in MRC-5 cells, indicating its specific activitty towards cancer cells 
(Liu et aI. , 20 11 b). 
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Figure 4.1 Growth inhibition curves of CDKI-71 for different treatment time points. 
HCT-116, A2780 and MRC-5 cells were treated with CDKI-71 for a range of concentrations at 
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24h, 48h or 72h, respectively. Mean values and SO were obtained from 3 independent 
experiments. 
4.3 Induction of apoptosis 
Types of cell death include apoptosis, autophagy, mitotic catastrophe, necrosis 
and senescence. Several methods were used to prove that CDKI-71 induced 
apoptosis in cancer cells, including cell morphology observation, caspase 317 
induction assay and annexin V /PI double staining. 
To investigate the morphological changes, HCT-116 and A2780 cells were 
seeded into 96-well plates at IS00/well. Cell images were taken after 72 hours 
treatment with DMSO vehicle control or I J,lM CDKI-71 (Figure 4.2). Cells 
grew quicldy in the vehicle control group, with nearly 100% and 80% 
confluency for HCT -116 and A2780 cells, respectively. However, the growth 
of cells was arrested by CDKI-71, with cell confluency less than 10% in both 
cell lines. The entire surface can be observed for the HCT -116 and A2780 
vehicle controls. In contrast, cell fragments and apoptotic bodies can be clearly 
detected microscopically after CDKI-71 treatment in both HCT-116 and 
A2780 cells (Figure 4.2), suggesting that cell death is due to apoptosis (Liu et 
aI.,201Ia). 
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Figure 4.2 Images of cell death after CDKI-71 treatment. HCT-116 or A2780 cells were 
treated with l ~ M M CDKl-71 for 72 hours. DMSO vehicle treatment was used as negative 
control. 
Caspase activation is an important biochemical feature of apoptosis. Induction 
of caspase 3/7 activity was also observed in HCT-116, A2780 or MRC-5 cells 
after treatment with either CDKl-7l or flavopiridol following 24 hours 
exposure (Figure 4.3). 
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Figure 4. 3 Induction of caspase 317 activity in cancer cell lines HCT -116 and A2780, and 
fibroblast MRC-S after treatment with CDKI-71 (A) or flavopiridol (8) for 24 hours. 
Vertical bars represent the mean ± SD of three replicates. Values significantly (p ~ ~ 0.05) 
different from DMSO vehicle control were marked with an asterisk (*). 
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Importantly, CDKI-71 induced caspase 3/7 activity significantly in both HCT-
116 and A2780 cells at 0.5 IlM or above, but no such activity was detected in 
MRC-5 cells below 5 IlM (Figure 4.3 A). In contrast, flavopiridol activated 
caspase 3/7 at 0.1 IlM in the cancer cell lines and at 0.2 IlM in MRC-5 cells 
(Figure 4.3 B). 
The membrane phospholipid phosphatidylserine (PS) is translocated from the 
inner to the outer leaflet of the plasma membrane during the early stage of 
apoptosis, thereby exposing PS to the external cellular environment. Annexin V 
is a Ca2+ dependent phospholipid-binding protein that binds tightly to PS. 
When annexin V is conjugated to fluorochromes, such as Fluorescein 
isothiocyanate (FITC), this format retains its high affinity for PS and binds to 
cells with exposed PS, thus serving as a sensitive probe for flow cytometric 
analysis of cells in the early stages of apoptosis. 
Propidium iodide (PI) is a 668.4 Da fluorescent molecule that is used as a DNA 
stain for flow cytometry to evaluate cell viability or DNA content in cell cycle 
analysis. Healthy cells with intact membranes exclude PI, whereas PI can 
penetrate the membranes of dead cells. Staining with FITC annexinV is usually 
used in conjunction with PI to identify early apoptotic cells (PI negative, FITC 
annexinV positive). For example, viable cells are FITC annexinV and PI 
negative; early apoptotic cells are FITC annexin V positive and PI negative; 
and late apoptotic or dead cells are FITC annexin V and PI positive. During 
long time treatment, apoptotic cells usually move from FITC annexinV and PI 
double negative (viable), to FITC Annexin V positive and PI negative (early 
apoptosis, membrane integrity is retained) and finally to FITC Annexin V and 
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PI double positive (end stage apoptosis and death). Progression through these 
three stages can be used to confirm cell apoptosis. 
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Figure 4.4 Induction of caspase-dependent apoptosis in HCT -116 cells. HCT -116 cells 
were exposed to different doses ofCDKl-71 or flavopiridol, with or without Z-VAD-fmk, for 
24 h or 48 h and analysed by annexinV/PI strained D A content (The data are representative 
of three replicate experiments). 
Induction of apoptosis by CDKI-7l or flavopiridol was analyzed by 
annexinVIPI double staining in HCT-ll6 (Figure 4.4), A2780 (Figure 4.5) 
and MRC-5 cells (Figure 4.6). In HCT-ll6 cells, both CDKI-71 and 
flavopiridol induced dose- and time- dependent apoptosis. CDKI-7l induced 
early apoptosis starting from 0.5 flM (G1so concentration) after 24 hours, which 
is indicated by significant increase of FITC annexin V in the bottom right 
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chamber (A4). After 48 hours treatment, increased late cell death population 
was also detected (11.5% and 20.4% for 0.5 JlM and 2.5 JlM treatment, 
respectively) in the top right chamber (A2). The starting concentration (0.5 JlM) 
was consistent with the observed caspase 317 activity and MTT growth 
inhibition assay. Like CDKI-71, flavopiridol also induced apoptosis in a dose-
and time-dependent manner at concentrations above 0.1 JlM. 
Apoptosis was suppressed significantly when cells were treated with 2.5 JlM 
CDKI-71 and 50 JlM Z-VAD-fmk, a pan-caspase inhibitor. After 48 hours 
treatment with 2.5 JlM CDKI-71, the percentage of cells in early and late 
apoptosis was 10.0% and 20.4% respectively. However, this was reduced to 1.4% 
and 3.2% when cells were treated with 50 JlM Z-VAD-fmk together with 2.5 
JlM CDKI-71, suggesting a caspase-dependent mechanism of apoptosis 
induction for CDKI-71. Similar results were obtained after exposure to 
flavopiridol. 
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Figure 4. 5 Induction of caspase-dependent apoptosis in A2780 cells. A2780 cells were 
exposed to djfferent dose ofCDKI-71 or flavopiridol, with or without Z-VAD-fmk, for 24 h 
or 48 h and analysed by annexinV/PI strained D A content (The data are repre entative of 
three replicate experiments). 
Induction of caspase-dependent apoptosis was also observed in A2780 cells 
after CDKI-71 or flavopiridol treatment at the same concentrations (Figure 
4.5). Importantly, MRC-5 cells were less sensitive to CDKI-71 treatment 
compared to the cancer cell lines, and apoptotic cells were only detected on 
treatment with CDKI-71 at 5 IlM, which was 10 times higher than the effective 
concentration in cancer cells (Figure 4.6). This result is consistent with the 
MIT assay. In contrast, flavopiridol induced apoptosis in MRC-5 cells after 
exposure to concentrations from 0.2 IlM, showing similar potency in cancer 
and normal cell lines (Liu et al., 2011b). 
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Figure 4.6 Induction of caspase-dependent apoptosis in MRC-S cells. MRC-S cells were 
exposed to different doses ofCDKl-71 or flavopiridol , with or without Z-VAD-fmk, for 24 h 
or 48 hand analy ed by annexinVIPI strained D A content (The data are representative of 
three replicate experiments). 
4.4 Cell cycle effect 
Lacking cell cycle roles, CDK9 regulates RNAPII transcription. Reduction of 
CDK9 levels by siRNA had no appreciable effect on cell cycle distribution 
(Cai et aI., 2006b), whereas inhibition of CDK 1 and CDK2 may arrest cells at 
G21M boundary and G 1 phase respectively (Lapenna and Giordano, 2009; 
Shapiro, 2006). 
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The effect of CDKI -71 on cell cycle progression was investigated in HCT -116 
and MRC-5 cells by fluorescence activated cell sorting (F ACS). Perrneabilized 
cells were stained with PI and were detected and quantified using flow 
cytometry (Figure 4.7). 
No cell cycle effect was observed after the treatment of HCT -116 cells with 
O . 5 ~ M M CDKI-71 for 24 hours compared to DMSO control. Treatment with 2.5 
IlM (5 x GIso by MTT assay) CDKI-71 caused accumulation of cells in G2/M 
of the cell cycle and the same cell-cycle profile was observed with 0.1 IlM 
flavopirido1. As shown previously, 0 . 5 ~ M M CDKI-71 treatment induced 
apoptosis significantly in HeT -116 cells (Figure 4.4), suggesting a cell cycle-
independent mechanism of cell death induction. In MRC-5 cells, no G21M 
arrest was observed after CDKI-71 treatment at 5 IlM, at which concentration 
apoptosis occurred. However, 0.2 IlM (apoptosis concentration) flavopridol 
induced G21M accumulation (Liu et aI., 2011b). 
101 
A 
B 
.'!l 
.. 
= o 
.. 
... 
u 
~ ~ Pre-Gl 
1.9% 
DMSO 
GliO 
45.2% 
G2IM 
29.1" 
---
HCT-116 
24h 
I ~ ~
~ ~
Pre-Gl 
2.4% 
Gl/O 
47.1% 
0.1 11M flavopiridol 
~ ~ Gl/O 
Pre-Gl 33.3% 
4.4% 
--
S 
8.8% 
'023 
~ - - - - - - - - - - - - - - - - - - - - ~ - - - - - - - - - - - - - - ~ ~ ' ~ ~
DMSO 
Pre-Gl Gl/O 
1.4% 46.5% 
S 
16.4" 
MRC-5 
24h 
DNA content (FL 1) 
1023 
2.S"M CDKI-71 
Pre-Gl Gl/O 
1.2lI> 51Dl1> 
S 
24.6" 
0.1 11M flavopiridol 
Pre-Gl Gl/O 
1.3% 44.6" 
S 
27.4" 
'''' 
____ _'_ _____________ )7 '023 
DNA content (FL I) 
~ ~
2.5I1MCDKI-71 
Pre-Gl 
2.7% 
Gl/O 
24.3% 
S 
15.1' 
O.5I1M flavopiridol 
~ ~ Gl/O 
Pre-G 1 27.6'1 
3.5% 
-I-
Pre-Cl Cl/o 
1.4" 4a.5" 
S 
21.8% 
0.211M flavopiridol 
Pre-G l Gl/O 
5.0'lI: 45.3" 
I ~ ~
1023 
1023 
10Zl 
Figure 4.7 Cell cycle effects of CDKI·71 or f1avopiridol. HCT-116 (A) or MRC-5 (8) cells 
were treated with different concentrations ofCDKJ-71 or flavopiridol for 24 hours (The data 
are representative of three replicate experiments). 
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4.5 Inhibition of cellular RNAPII CTD phosphorylation 
CDK9 regulates transcription elongation by phosphorylating serine 2 (Ser 2) on 
the CTD of RNAP II, while CDK7 phosphorylates Ser 5 during transcription 
initiation. Immunoblot analysis of HCT-116 cells after treatment with CDKI-
71 or flavopiridol for a period of24 hr indicates that 0.5 J.lM CDKI-71 reduced 
phosphorylation at Ser-2 of RNAPII CTD significantly, suggesting cellular 
CDK9 inhibition (Figure 4.8). Phosphorylation at Ser-5 was only reduced 
when the cells were treated with 2.5 J.l.M CDKI-71, confirming the relative 
selectivity for CDK9 over CDK7. In contrast, flavopiridol decreased the 
phosphorylation of both Ser-2 and Ser-5 from 0.1 J.l.M, indicating similar 
potency for both CDK7 and CDK9, despite its apparent selectivity for CDK9 
over CDK7 in the kinase assays. 
The phosphorylation status of substrates specific for CDK21 A and CDK liB 
were also investigated by western blots. Reductions in the levels of 
phosphorylated pRbT821 (CDK2/A) and p-PPla (CDKIIB) were caused by 
CDKI-71 at 1.0 and 2.5 J.l.M, respectively, confirming the lower inhibitory 
activity against these enzymes compared to that of CDK9 (Figure 4.8). In 
contrast, flavopiridol suppressed cellular CDK2 and CDK 1 at the 
concentrations of 0.1 and 0.2 J.l.M respectively, once again pointing to the 
relatively less selective inhibitory activity of this drug (Liu et aI., 20 II b). 
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Figure 4.8 Inhibition of RNAPII CTO phosphorylation and other cell cycle COKs by 
Western blot analysis. HCT-116 cells were treated with indicated concentration of DKI -7 1 
or flavopiridol for 24 hr. 
4.6 Effect on gene transcription 
Since CDK9 regulates transcription elongation, CDK9 inhibition should 
suppress the synthesis of messenger RNA (mRNA) from genes regu lated by 
CDK9. To investigate the effect of CDKT-71 treatment on gene transcription, 
DNA microarray (30,000 gene probe) was performed on A2780 cells after 
treatment with CDKT-71 (1 /lM) or flavopiridol (0 .2 /lM) for 4 hours. [n 
comparison to untreated A2780 cells, CDKT-71 changed expression of 158 
probes by at least two fold (llog21> 1) (Appendix One). The lowest log2 ratio 
was -1.77 and the highest was 1.29. Of note, 141 probe sets were down-
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regulated and only 17 probe sets were up-regulated. Hierarchical clustering 
was further perfonned for the 158 probe sets to compare the gene changes of 
CDKI-71 and flavopiridol (Figure 4.9 A). EASE software (Hosack et aI., 2003) 
was used to identify over-represented gene categories. These 158 probe sets 
were further divided into 4 clusters depending on different changes in gene 
expression induced by CDKI-71 or flavopirido1. 
Cluster 1 (green) includes 138 probes downregulated by both CDKI-71 and 
flavopiridol. The main gene categories enriched in cluster I contains: 
transcription (26 hits), regulation of transcription (23 hits). 
Cluster 2 (blue) exhibits the 3 probes (NM_032595: protein phosphatase 1, 
regulatory subunit 98, spinophilin, NM_020533: mucolipin I and NM-004963: 
guanylate cyclase 2C) which were only down-regulated by CDKI-71. However, 
it's not accurate to analyze the gene category due to the low probe quantity. 
Cluster 3 (red) includes probes up-regulated by CDKI-71 that were also up-
regulated or not regulated by flavopiridol. 10 genes were obtained from EASE. 
Cluster 3 maximally enriched biological process gene ontology (GO) includes: 
transport (3 hits), catalytic activity (5 hits) and transporter activity (4 hits). 
Since many functional genes were down-regulated, the cellular feedback loop 
may facilitate the over-expression of genes regulating catalytic or transporter 
activity to overcome the lack of down-regulated genes. It is also possible that 
these up-regulated genes were negatively regulated by some genes which were 
decreased by the treatment. 
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Cluster 4 (yellows) contains two probe sets (AC022215 and NM_020142) 
which were up-regulated by CDKI-71 but down-regulated by flavopiridol. The 
function of AC022215 is still not clear, while NM_020142 gene encode NADH: 
ubiquinone oxidoreductase MLRQ subunit homolog and may transport 
electrons from NADH to ubiquinone. However, no further analysis can be 
performed because of the very low probe amount. 
Flavopiridol was reported to inhibit transcription globally in a similar way to 
two transcription inhibitors, actinomycin D and DRB (Lam et al., 200 I). The 
majority of genes were down-regulated after CDKI-71 (141 out of 158 genes) 
or flavopiridol (142 out of 158 genes) treatment, suggesting CDKI-71 is also a 
transcription inhibitor. 
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Figure 4.9 Gene expression patterns of A2780 cells treated with CDKI-71 or flavopiridol. 
A: Hierarchical clustering was performed for the158 probe sets whose expression changes 
more than 1 log (jlog2 j> \). Each column is a single experiment comparing two cDNA 
populations; treated samples were labelled red (Cy5) and untreated samples were labelled with 
green (Cy3). The red-to-green (Log2 Cy5/Cy3) ratio reflects hybridization to that spot and 
relative gene expression. Red indicates Log2 Cy5/Cy3 value > 0, green indicates Log2 
Cy5/Cy3 value < O. The values were depicted according to the colour scale shown on the top. 
Four distinct clusters of genes are marked on the right. B: Changes of expression of anti-
apoptotic proteins 8cl-2 and Mc1-l 
4.7 Down-regulation of anti-apoptotic protein Mcl-l 
and up-regulation of p53 
Anti-apoptotic proteins inhibit apoptosis by inhibiting the function of pre,-
apoptotic proteins (section 1.1.4.2). Cancer cells often have a high demand for 
transcription and translation of anti-apoptotic proteins to resist programmed 
cell death (Koumenis and Giaccia, 1997). Many of these proteins have short 
half lives at both the mRNA and protein levels. The expression of several 
antiapoptotic proteins, such as Mel-I, Bel-2, were reported to be regulated by 
CDK9. Western blot analysis was performed in A2780 cells to fmd the cellular 
mechanism of action for CDKl-71 (Figure 4.10). 
Similar to RCT -116 cells, treatment of A2780 ovarian cancer cells with CDKl-
71 at 0.5 J.1M for 24 hours or I J.1M for 6 hours resulted in a significant 
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reduction in the phosphorylation of Ser-2, but not Ser-S, suggesting selective 
CDK9 inhibition. Mel- l anti-apoptotic protein was reduced significantly by the 
same treatment, but no effect on XIAP or Bcl-2 proteins was detected. 
Induction of apoptosis was indicated by PARP cleavage at o.s /lM . Similar 
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Figure 4.10 Effects on antl-apoptot ic proteins and the pSJ pathway by Western blot 
analysis in A2780 cells. Cells were treated with indicated concentrations of DKI-7 1 or 
flavopiridol for 24 hours (A) or 6 hours (8). 
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results were obtained after flavopiridol treatment. Blockade of RNAPII 
transcriptional activity reduced the levels of the transcripts and their encoded 
proteins. Mcl-l but not Bcl-l protein was found to be particularly sensitive to 
CDKI-71 or flavopiridol treatment. This is consistent with the results reported 
before. For example, Mcl-l protein decreased in cancer cells after incubation 
with flavopiridol or SNS-032, but the expression of Bcl-2 remained unchanged, 
even though its mRNA was reduced (Chen et aI., 200S; Chen et aI., 2009). The 
specific motifs of the mRNA or protein sequences signalling for degradation 
may be responsible for the different responses. The adenylate/uridylate-rich 
elements (ARE) -mediated Mc1-1 and Bcl-2 mRNA decay may explain their 
short mRNA half lives (Chen and Shyu, 1995; Schiavone et aI., 2000). PEST 
regions (rich in proline, glutamic acid, serine, and threonine), on the other hand, 
identify proteins for rapid destruction (Rechsteiner and Rogers, 1996; Rogers 
et aI., 1986). The primary protein structure of Mcl-l confirms its susceptibility 
to rapid intracellular proteolysis (tll2 = O.S - 1 hour) while Bc1-2, which does 
not have a PEST region, is a long-lived protein with t1/2;;;: 10 - 24 hours (Reed 
et aI., 1987). This may explain why only Mc1-1 protein was reduced after 24 
hours treatment. 
MRC-S fibroblast cells were treated with CDKI-71, flavopiridol or cisplatin for 
24 hr (Figure 4.11). CDKI-71 reduced phosphorylated Ser-2, Ser-S and Mcl-l 
protein at 5 J.1M. Induction of apoptosis also occurred at 5 J.1M, demonstrated 
by P ARP cleavage and annex in V /PI assays. These data confirmed that the 
cancer cells were more sensitive (IO-fold) to CDKI-71 than the untransformed 
MRC-S cells. However, MRC-5 cells also seem to rely on Mcl-I, but the 
reasons for this remain unresolved. In contrast, treatment with 0.2 J.1M 
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flavopiridol resulted in reduced levels of phosphorylated Ser-2 and Ser-5 as 
well as a reduction in Mc1-1 expression, demonstrating less selectivity 
compared to CDKI-71. 
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Figure 4.11 Effects on anti-apoptotic proteins and the p53 pathway by Western blot 
analysis in MRC-S cells. Cells were treated with indicated concentrations of CDKI-7 1 or 
flavopiridol for 24 hours . 
Mcl-1 prevents mitochondrial outer membrane permeabilization and 
cytochrome C release (Danial, 2007; Danial and Korsmeyer, 2004); down-
regulation of Mcl-1 by CDKI-71 and flavopiridol may there fore facilitate the 
release of cytochrome C from mitochondria leading to induction of apoptosis. 
As tumour cells appear to be dependent on Mcl- l for survival (Michels et aI. , 
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2005), this is an excellent target for CDK9 inhibitors for the induction of 
apoptosis. 
Induction of p53 was observed on treatment with CDKI-71 at apoptotic 
concentrations which were 0.5 and 5 J.lM in A2780 and MRC-5 cells, 
respectively. Expression of p53 is tightly regulated by its negative regulator 
MDM2, a short half-life protein targeting p53 degradation, which was also 
reduced by CDKl-71 and flavopiridol (Figure 4.10 and 4.11). Importantly, 
CDKI-71 decreased Ser-2 phosphorylation, Mcl-l and MDM2 protein at the 
same concentration, suggesting the down-regulation of MOM2 may also be 
due to CDK9 inhibition. In addition, COKI-71 up-regulated p21 in a dose-
dependent manner. This is consistent with the result of a previous study 
demonstrating that p21 was induced by DRB, the most selective CDK9 
inhibitor identified to date (Blagosklonny et aI., 2002). Importantly, CDKI-71 
showed similar sensitivity between p53 wild type, p53 null, and p53 mutant 
cells in our MIT assays, suggesting that CDKl-71-induced apoptosis is p53 
independent and that the increase of p53 is a molecular consequence of CDK9 
inhibition-mediated MDM2 down-regulation. 
4.8 Flavopiridol induces DNA double-strand breaks 
Flavopiridol demonstrated potent anti-proliferation effects (G150 <IOOnM) in 
the cell lines tested, with no obvious tumour-type or tumour selectivity, which 
is consistent with reported data using the US National Cancer Institute (NCI) 
60 human tumour cell lines (Oai and Grant, 2003). Flavopiridol also killed 
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eLL cells and nonnal mononuclear cells at similar concentrations (Byrd et aI. , 
\998). 
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Figure 4.12 Induction of y-H2AX by flavopiridol. Western blot analysis was performed in 
A2780 (A) or MRC-5 (B) cells after CDKI-71 , flavopiridol or cisplatin treatment for 6 hours. 
Images of permeabilized MRC-5 cells were taken after labelling with a yH2AX primary 
antibody and an Alexa Fluor 488 secondary antibody (C) D A was counterstained with 
Hoechst dye. 
Given that the kinase inhibition proflle of CDKI-71 and flavopiridol were 
similar but their cytoxicity profiles were not, we suspected that DNA damage 
may be another outcome of flavopiridol treatment. Consequently, we 
investigated the effects of flavopiridol and CDKI-71 on the expression of y-
H2AX (Figure 4.12). 
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H2AX is a variant of histone H2A required to maintain genomic stability 
(Celeste et aI., 2002). y- H2AX (phosphorylated H2AX) has been shown to be a 
sensitive marker of DNA double strand breaks induced by DNA-damaging 
agents (Paull et aI., 2000). Western blot analysis of A2780 cells after treatment 
with 0.2 J.1M flavopiridol or 5 IlM cisplatin for 6 hours showed elevated y-
H2AX, but no effect was observed for CDKI-71 treatment at 2 JlM (Figure 
4.12 A). In MRC-5 cells y-H2AX was also increased by 0.2 JlM flavopiridol, 
while 5 JlM CDKI-7l showed no significant differences in the level of y-
H2AX compared to DMSO treatment (Figure 4.12 B). Induction of y-H2AX 
foci was also detected after 6 hours flavopiridol treatment at 0.2 JlM in MRC-5 
cells (Figure 4.12 C). 
Comet assay under alkaline conditions was performed on MRC-S cells after 
treatment with 5 JlM CDKI-71 or 0.2 JlM flavopiridol for 6 hours to further 
confirm the DNA damage effect of flavopiridol, and to estimate the damage 
distribution in a population of cells (Figure 4.13). This assay is based on the 
ability of denatured or cleaved DNA fragments to migrate out of the nucleus, 
whereas undamaged DNA strands are too large and do not leave the cavity 
under electrophoresis. Significant numbers of cells with DNA double-strand 
breaks were observed, as evidenced by the formation of the comet, enlarged 
tail and increased tail intensity, after treatment with flavopiridol (Table 4.4). In 
contrast, no comet cells can be detected after CDKI-71 or DMSO vehicle 
control treatment. 
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Figure 4.13 Comet assay (single-cell gel electrophoresis) on MRC-5 cells treated with 
DMSO vehicle, CDKI-71 or flavopiridol for 2 hours. The comet cells with DNA double-
strand breaks were detected by tail length and intensity, and some of these cells can be 
visualized (indicated with the arrows). 
No significant indication was observed in the microarray. It might be due to the 
genes related to DNA damage were down-regulated by CDK9 inhibition or the 
response maybe at the translation level. 
Table 4.3 Tail length and Tail intensity after CDKI-71 or f1avopiridol treatment in the 
comet assay. 
Treatments Tail Length Tail Intensity 
.... m 0/0 
DMSO 15.94±5.98 8.38±6.78 
5)lM CDKI-71 15.47±5.65 8.41±8.55 
O.2)lM flavopiridol 29.29±13.13* 24.14±20.68* 
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IJlM flavopiridol 26.97±8.99* 24.97±19.31* 
Values significantly different (p < 0.05) from DMSO treated cells are marked with an asterisk 
(*). 
As the first CDK inhibitor in clinical trials, flavopiridol has attracted much 
interest in the past decade. Previous studies showed the evidence that 
flavopiridol interacts with DNA in vitro (Bible et at, 2000). Analysis of the 
pattern of flavopiridol- induced cytotoxicity in the NCI-tumour cell line panel 
using the COMPARE algorithm showed that flavopridol shares similar 
mechanisms of action to intercalating or DNA-damaging agents, such as 
ecteinascidin 729, chromomycin A3, actinomycin D (Bible et at, 2000). 
However, the biological significance has not been determined. Here we report 
the first cellular evidence that flavopiridol induces DNA double-strand breaks 
in cancer cells and fibroblasts. 
4.9 Cellular model of action of CDKI-71 and 
flavopiridol 
It has been observed that CDKI-71 and flavopiridol have similar activity at the 
kinase level, but flavopiridol is more potent in cells. In addition, flavopridol 
appears to have no selectivity between CDK9 and CDK7 in cells. These 
observations may arise from the ability of flavopiridol to intercalate into the 
DNA double strands, which may serve as a template to facilitate the 
association of flavopiridol with the RNAPII CTD and therefore inhibit activity 
of CDKs 9 and 7 (Figure 4.14). However, the cellular distribution model is 
only a hypothesis and further experiments are needed to prove it. Alternatively, 
the DNA damage response of flavopiridol may down regulate CDK7 activity 
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and the DNA intercalated flavopiridol would also arrest the function of 
RNAPII. 
1 C ~ ~ioplnslll ® 
7 
71 
RNAPII 
Nucleus 
71 
: Hnvopiridol 1 :CDKI-71 
Figure 4.14 Cellular distribution model for CDKI-71 and flavopiridol. As flavopiridol 
binds to double strand D A, D A double strands may form a reservoir for flavopiridol. Due to 
equilibrium effect, the concentration of unbound flavopridol around the D A trands should be 
higher than other area outside the nucleu . After tran cription initiation, RNAPII traverse one 
strand of D A (the template trand) and uses base pairing complementarity with the D A 
template to create an R A copy. Therefore, R APII is in close proximity to DNA which is the 
reservoir of flavopiridol. CDK7/Cyclin Hand CDK9/Cyclin T phosphorylate SerS and Ser2 
ites of R APII , re pectively. The locally high concentration of flavopiridol facilitates it 
inhibitory activity and conceals flavopiridol's selectivity towards CDK7 and CDK9. As a 
tran cription inhibitor, flavopiridol or CDKl-71 must enter the nucleu . As we know, different 
cell types should have different membrane penetration characteristic or organelle distribution 
for anti-cancer agents. The D A binding effect for flavopiridol ensures the high concentration 
for flavopiridol in different cell types. This may explain why flavopiridol inhibit CDK9 at 
similar concentrations in HCT-ll6, A2780 and MRC-5 cells, but CDKl-71 has a IO-fold 
difference. 
Based on the above experiments, the cellular similarity and difference between 
CDKI-71 and flavopiridoI are shown in Figure 4.15. CDKI-71 induces 
caspase-dependent apoptosis potently which was closely associated with the 
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inhibition ofRNAPII phosphorylation at serine-2. This was caused by effective 
CDK9 inhibition and resulted in the downstream inhibition of anti-apoptotic 
protein Mcl-I. No correlation between apoptosis and inhibition of cell-cycle 
CDKs 1 and 2 was observed and low concentrations of CDKI-71 induced 
apoptosis without cell cycle effects. However, flavopiridol induced G21M 
arrest at the lowest concentration to induce apoptosis (0.1 ~ M ) , , suggesting 
different mechanism of action contributes to flavoprido1 induced apoptosis. 
Moreover, flavopiridol was proved to intercalate into DNA and induce DNA 
damage, which can also induce apoptosis in cancer cells or non-transformed 
cells. 
CDKI-71 Flavopiridol Cell cycle arrest 
/ 
CDK9 inhibition 
Down-regulation of 
Anti-apoptotic protein 
Mc1-1 
DNA intercalating 
/ 
Apoptosis 
Figure 4.15 Cellular model of action of CDKI-71 and flavopiridoI.Both CDKI-71 and 
flavopiridol are potent transcriptional CDK9 inhibitors. By reducing anti-apoptotic protein 
Mel-! , they trigger apoptosis in cancer cells regardless of the p53 and Rb status. However, 
flavopridol induces D A double-strand break , which also can induce apoptosis in cancer or 
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non-transformed cells. The apoptosis induced by CDKI-71 is not related to cell cycle effects. 
In contrast, flavopiridol causes G2/M. 
4.10 Conclusion 
In this section, it has been demonstrated that by inhibiting CDK9 regulated 
RNAPII transcription, CDKI-71 reduces anti-apoptotic protein Mc1-1 and 
thereby renders cells sensitive to apoptosis, which is caspase-dependent but 
p53-independent. This comparative study also shows similar CDKI-71 
concentrations cause significant reduction in the levels of the anti-apoptotic 
protein Mcl-l and MDM-2 in cancer cells, which is also observed after 
flavopiridol treatment. However, unlike flavopiridol, CDKI-71 does not induce 
DNA damage and is less toxic to normal cells. This presumably contributes to 
its ability to selectively induce apoptosis in cancer cells. Based on these 
findings, CDKI-71 has the potential to be developed as an anti-cancer agent, 
and a better therapeutic window than flavopiridol could be predicted. 
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Chapter Five: In vitro anti-tumour 
mechanism of a novel eyelin-dependent 
kinase inhibitor CDKI-83 
5.1 Introduction 
Targeting CDKs should counteract the unchecked proliferation of transformed 
cells by modulating the functions of CDKs in the regulation of the cell cycle. 
However, the conventional understanding of the roles of CDKs in the cell cycle 
regulation has been challenged (Cai et aI., 2006b). Cancer cell lines and some 
embryonic fibroblasts lacking CDK2 proliferate normally and CDK2 knockout 
mice are viable, suggesting that CDK2 performs a nonessential role in cell 
cycle control (Barriere et aI., 2007; Berthet et aI., 2003). Furthermore, 
Mammalian cells without CDKs 4 and 6 enter the cell cycle normally 
(Malumbres et aI., 2004). It has been demonstrated the catalytic activity of 
CDKI is sufficient for cell-cycle progression (Santamaria et aI., 2007). 
Specific CDKI depletion in some cancer cells results in accumulation of cells 
with G21M DNA content, but causes only minimal cell death (Vassilev et aI., 
2006). It has been shown that the combined depletion of CDK9, CDKI and 
COK2 resulted in effective induction of apoptosis through both RNAPII CTO-
and E2F mediated effects (Cai et aI., 2006b). 
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In an effort to discover novel CDK inhibitors, a class of 2,4,5-tri-substituted 
pyrimidines were identified using structure-guided and analogue design 
approaches in our group. A number of inhibitors exhibited anti-prolifemtive 
activity in human cancer cells. One of the lead compounds CDKI-83 was found 
to be a potent CDK inhibitor against CDK9 and CDKI (Uu et a1., 201la). 
5.2 CDKI-83 is a potent inhibitor ofCDK9 and CDKI 
The structure and inhibitory specificity of 4- (4-methyl-2-
(methylamino )thiazol-5-yl)-2-( 4-methyl-3 (morpholinosulfonyl)phenylamino) 
pyrimidine-5-carbonitrile (CDKI-83) is shown in Figure 5.1. CDKI-83 
inhibited CDK9ITI and CDK lIB potently with Ki values of 21 nM and 72 nM, 
respectively. This compound also targeted other CDKs but was less effective 
against CDK2IE, CDK41D and CDK71H with Ki values of 232, 290 and 405 
nM, respectively. To determine the selectivity, CDKI-83 was also tested 
against a panel of non-CDK kinases (Figure 5.1 B) at 5 jJ.M. This compound 
was not active against protein kinase A, B, C, CaMKII, PDGFp or MAPK, and 
showed low activity against Src, Lck and Abl. 
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Figure 5.1 Structure and In vitro kinase activity of CDKI-83. A: chemical structure; B: 
Kinase activity after treatment with 511M COKI·83 as a percentage of untreated. C: Apparent 
inhibition constants (Ki) of COK inhibition. Kinase inhibition was measured by radiometric 
assay using the Millipore KinaseProfiler services. Ki values were calculated from ICso values 
and the appropriate Km (A TP) values for each kinase. 
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5.3 CDKI-83 is a potent anti-proliferative agent and an 
effective apoptotic inducer 
The A2780 ovanan cancer cell line was used to investigate the cellular 
mechanism of action of CDKI-83. The anti-proliferative activity was measured 
using MTT assay after 24, 48 or 72 hours treatment (Figure 5.2). Sharp 
decreases in the growth inhibition curves were detected after 48 or 72 hours 
treatment with CDKI-83 between 0.1 11M and 111M. The GI50 values for 24, 48 
or 72 hours treatment were 0.97 ± 0.06 11M, 0.46 ± 0.02 ~ M M and 0.47 ± 0.04 
~ M , , respectively. 
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Figure 5.2 Growth inhibition curves of CDKI-83 for different treatment time points. 
A2780 cells were treated with CDKl-83 for a range of concentrations at 24h, 48h or 72h, 
respectively. Mean value and SD were obtained from 3 independent experiments. 
Caspase-3 activity was measured in A2780 cells on treatment with CDKI-83 
for 24 or 48 h to fmd out whether the anti-proliferative effect of CDKI-83 was 
124 
a consequence of induction of apoptosis. The caspase-3 activity was increased 
significantly after CDKI-83 treatment at 1 ~ ~ or above, compared with DMSO 
vehicle control (Figure 5.3). 
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Figure 5.3 Induction of caspase-3 activity in A2780 ceUs after treatment with CDKI-83 
for 24 or 48 hours. Vertical bars represent the mean ± SO of three independent experiments. 
Values significantly (p S 0.05) different from OMSO vehicle control were marked with an 
asterisk (*). 
CDKl-71 induced dose- and time- dependent apoptosis, which was proved by 
AnnexinVIPI double staining (Figure 5.4). Treatment of A2780 cells with 1 
~ ~ CDKI-83 for 24 h resulted in 25% cells in early apoptosis and 6.3% in late 
apoptotsis. On extending the treatment to 48 h the apoptotic cell population 
was significantly increased to 36.5% and 20.6% in early and late apoptosis, 
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respectively, while for the same time period 5 ~ ~ CDKI-83 caused 76.9% cell 
death (48.1 % and 38.8% in early and late apoptosis, respectively). 
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Figure 5.4 Detection of apoptosis by flow cytometry analysis after Annexin V-PI double 
staining. A2780 cells were exposed to CDKl-83 for 24 or 48 hours and analy ed by 
annexinVIPI strained D A content. 
These results obtained from CDKI-83 are consistent with those of CDKI-71, 
suggesting these two CDK inhibitors may have similar cellular mode of action 
(Liu et aI., 2011a). 
5.4 CDKI-83 induces cell arrest in G2 phase 
As the only nonredundant cell cycle regulator, CDKI plays key roles during 
late G2 and Mitosis (Nigg, 2001). CyclinB/CDKl complex regulates late G2 
and mitosis by phosphorylating substrates and facilitating G21M transition. 
126 
Therefore, CDKI inhibition would make cells incapable of initiating mitosis 
and should arrest cells at the G21M border (Vassilev, 2006). 
11'1 
... 
C 
:::l 
o 
U 
Q./ 
U 
DMSO 
GllO 
68.7% 
Pre-Gl 
6.0% S 
16.5%G2/M 
~ ~ 8.3% 
0-------< 
1 ~ M C D K I - 8 3 3
.----,GllO 
~ ~ 44.1% 
Pre-Gl 
22.0% S 
12.5%G2/M 
19.9% 
------
DNA content 
1023 
O . S ~ M M CDKI-83 
G1/0 
63.9% 
Pre-G1 
6.7% S 
16.4%G2/M 
_ 12.1% 
~ ~
S ~ M C D K I - 8 3 3
Sl '---G1/0 
os 22.9% 
Pre-Gl 
35.0% S 
11.8% G2/M 
- ~ % %
) 
1023 
1023 
Figure 5.5 Cell cycle effects in A2780 cells. A2780 Cells were treated with 0.5, I or 5 ~ M M
CDKI-83 for 24 hours. 
The effect of CDKI-83 on cell cycle progression was investigated by F ACS. 
Human ovarian cancer A2780 cells were treated with CDKI-83 for 24 hours. 
Cell cycle analysis indicated that the treatment of A2780 cells with O.5IlM 
CDKI-83 slightly increased the number of G21M cells comparing to DMSO 
treatment; IflM CDKI-83 however resulted in significant accumulation of cells 
with G21M DNA content (Figure 5.5). Increased population of cells containing 
sub-G 1 amount of DNA was also observed, indicating that cell death was 
induced by the compound (Liu et aI., 201Ia). 
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Mitotic index assay was perfonned to identify whether CDKI-83 induced 
mitotic arrest. Vincristine, which is a mitotic inhibitor was used as a positive 
control. There was a decrease in mitotic index after O.SIJ.M or 2IJ.M CDKl-83 
treatment (Figure 5.6), suggesting the G2/M arrest caused by CDKI-7 1 i due 
to the cell accumulation in G2 phase (Liu et al., 20 II a). 
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Figure 5.6 Effect on Mitotic Index in A2780 cells. A2780 cells were treated with OK I-
for 7 hours and the percentages of cel\s in mitotic were measured. OMSO vehicle and 0.5).lM 
vincristine were used as negative and positive controls respectively. Vertical bars represent the 
mean ± SO of three independent experiments . Values sign ifi cantly (p ~ ~ 0.05) different fr m 
OMSO vehicle control were marked with an asterisk (*). 
5.5 Cellular CDKI inhibition of CDKI-83 
During metaphase, PPla phosphatase, one of the substrates for CDK I complex, 
is phosphorylated at Thr32o. This phosphorylation inhibits PP I a phosphata e 
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activity and increases phosphorylation of proteins critical in mitosis. CDKI-83 
is shown to block the phosphorylation of PP- I a at Thr320 at ~ ~ I flM 
concentrations (Figure 5.7), indicating cellular CDKI inhibition (Liu et aI. , 
20 11 a) . In this experiment, inhibition of CDK 1 was observed after 24h, which 
is the same period used in the previous cell cycle analysis. However a shorter 
treatment time (2b - 6b) would be better to detect the original effect on the cell 
cycle proteins. 
CDKI-83, JIM 
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Figure 5.7 Effect on the phosphorylation status of C DKI substrate PPl« at Thrl2O. A27 0 
cells were incubated with 0.5, I, 2.5 or 5 11M CDI-83 for 24 hour . Data are representative for 
3 experiments. 
5.6 CDKI-83 reduces both mRNA and protein level of 
McI-l by targeting CDK9 
The ability ofCDKl-83 to inhibit cellular transcriptional CDK9/CDK7 activity 
was detennined by measuring the phosphorylated Ser-2/Ser-5 of RNAPII TD 
in A2780 cells. After 24 hours treatment, the phosphorylation of ser-2 was 
significantly reduced from I ~ ~ and completely inhibited by 2.5 f1.M (Figure 
5.8 A). However, little effect was observed on the phosphorylation of Ser-5 
and total RNA polymerase II, indicating CDKl-83 targeted the transcription by 
CDK9, but not CDK7. 
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Figure 5.8 Inhibition of CDK9 and reduction of survival factors In A2780 cells. A: ell ' 
were analysed by Western blot after 24h treatment with OK-83 at the concentrati n ' 
indicated. 8 : Effect on the levels of mRNAs determined by RT -P R following treatment with 
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1 or 5 IlM CDKI-83 for 6 or 24 hours. DMSO vehicle was used for comparison and l3-actin 
antibody was used as an internal control in each experiment. 
We further investigated whether inhibition of CDK9 regulated RNAPII 
transcriptional reduced the levels of those mRNAs and proteins with rapid 
turnover rates, such as Mel-l and Bel-2. RT-PCR was used to investigate the 
action of CDKI-83 on transcripts. CDKI-83 was capable of down-regulation 
the mRNA ofMel-l and Bcl-2 in a dose- and time-dependent manner as shown 
in Figure 5.8 B. Incubation of A2780 cells with lJ.LM CDKI-83 for 24 hours 
substantially decreased the mRNA of both Bcl-2 and Mel-I. Bcl-2 mRNA was 
more affected than the mRNA of Mcl-l. However, western blots showed Mel-l 
protein was reduced more significantly than Bel-l after CDKI-83 treatment 
(Figure 5.7 A). This pattern corresponds to the effects of clinic CDK inhibitors 
flavopiridol and SNS-032, which have been shown to reduce the mRNA of 
Bel-2, but are ineffective against its protein level (Chen et al., 2005),(Chen et 
aI., 2009). These observations correlate with the reported short half-life of Bel-
2 mRNA (2.5-4 h) and the longer half-life of Bcl-2 protein (10-24 h) 
(Blagosklonny et aI., 1996). 
As tumour cells appear to be dependent on Mel-l for survival (Michels et aI., 
2005), it is an excellent target for CDK9 inhibitors and the induction of 
apoptosis. As Mel-l prevents mitochondrial outer membrane permeabilization 
(MOMP) and cytochrome c release (Danial, 2007; Danial and Korsmeyer, 
2004), its downregulation by CDKI-83 may facilitate cytochrome c release 
from mitochondria and induce apoptosis through caspase activation. 
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5.7 Conclusion 
In order to cure complex disorders in cancer, absolute selectivity to one target 
might not be the best approach for cancer therapy. Combinations of targets 
rather than a single effect might yield better therapeutic agents (Knockaert et 
aI., 2002). COKI-83 is a nano-molar COK I and CDK9 inhibitor with potent 
anti-proliferative activity. This compound is capable of inducing apoptosis in 
cancer cells. By inhibiting cellular COK 1 and COK9 activities, CDKI-83 
arrests cells in 02 phase and reduces anti-apoptotic protein Mel-I, respectively. 
This study suggests that the combination ofCDK9 and CDK) inhibition results 
in effective induction of apoptosis in A2780 cells and COKI-83 has the 
potential to be further developed as a potent anti-cancer agent. 
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Chapter Six 
General discussion and conclusion 
The processes of hit-to-Iead and preclinical candidate optimization often take a 
long time in the modem drug discovery program. Due to the high cost of 
compounds generated from structure-based approaches and high throughput 
screening (HTS), focused screen of compounds with similar structures to 
previously identified hits is widely used in academia. Hundreds of compounds 
designed to target diverse kinases, including CDK9, CDK7 and Plkl have been 
synthesized by our group. In this project, a cell-based screening cascade was 
developed to classify compounds and identify effective transcription CDK 
(CDK7 and especially CDK9) inhibitors as lead candidates. 
Compounds were first tested by the MTT assay and 46 compounds with G I ~ ( ) )
values below 1 J.lM were further screened using a caspase-3 activation assay 
and a p53 stabilization assay. Candidates for transcriptional CDK9 inhibitors 
were selected from compounds which showed high potency in the anti-
proliferative assay and induced both caspase-3 activities and p53 levels at 
comparative concentrations. It was reported that the reduction of CDK9 level 
by siRNA had no significant effect on the cell cycle distribution (Cai et al.. 
2006a). In this screening cascade, a mitotic index assay was performed to 
evaluate cell cycle effect. Compounds S3-41 and CDKI-71 are the most potent 
CDK9 inhibitors identified. These two compounds showed comparative 
potency cross the MTT, caspase-3 activity and pS3 stabilization assays at 
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concentrations below 0.5 flM without significant effects on mitotic index, 
suggesting their anti-proliferative effect would be due to CDK9 inhibition. The 
kinase activity assay showed that our key compounds inhibited CDK9 at low 
nano-molar levels and proved the efficacy of the screening cascade. 
Cancer cells depend heavily on expression of anti-apoptotic proteins for 
survival (Koumenis and Giaccia, 1997). Some of the anti-apoptotic proteins 
have short half lives at both mRNA and protein level and thus they need the 
continuous activity of RNA polymerase II. Inhibition of transcriptional CDKs, 
such as CDK9, represents an attractive strategy for cancer therapy. McI-I has a 
very short half-life and its expression is highly sensitive to transcription. 
Down-regulation of Mcl-l is often sufficient to promote apoptosis in cancer 
cells (Derenne et aI., 2002). A novel small molecular CDK9 inhibitor CDKI-71 
was identified using our screening cascade and the detailed cellular mechanism 
was investigated and compared with a clinical CDK inhibitor, flavopiridol (Liu 
et aI., 2011b). 
Through inhibition of RNAPII phosphorylation at Ser-2, CDKI-71 and 
flavopridol decreased anti-apoptotic protein Mcl-l and induced caspase-
dependent apoptosis in cancer cells. Similar results were reported for other 
CDK9 inhibitors, including SNS-032 (Chen et aI., 2009). The majority of 
mRNAs that were changed in the microarray after CDKI-7] or flavopiridol 
treatment were down-regulated, including genes encoding transcription and 
transcription regulation. Since flavopiridol inhibits transcription globally in a 
similar way to actinomycin D and DRB (Lam et aI., 2001), the microarray 
results suggested that CDKI-71 was also a transcription inhibitor. Importantly, 
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non-transformed lung fibroblast cell lines showed resistance to C'DKI-71 
treatment. However, flavopiridol presented little selectivity between the cancer 
and normal cells. The first cell-based evidence that flavopiridol induces DNA 
double-strand breaks was provided in this study and that may explain why 
flavopiridol showed little selectivity. These results suggest that C'DKI-71 has a 
great potential to be developed as an anti-cancer agent with a better therapeutic 
window compared to flavopiridol. 
As the only essential cell cycle CDK, CDKI regulates cell cycle progression 
via phosphorylation of several substrates and facilitates 021M phase tmnsition 
(Nigg, 2001). The in vitro anti-tumour mechanism of another CDK inhibitor 
CDKI-83 was also investigated (Liu et aI., 2011a). CDKI-83 is a nano-molar 
CDKI and CDK9 inhibitor with potent anti-proliferative activity. Similar to 
CDKI-71, this compound reduces anti-apoptotic protein Mcl-l and is capable 
of inducing apoptosis in cancer cells. Unlike CDKI-71. CDKI-83 arrests cells 
in 02 phase by inhibiting cellular CDK 1. This study suggests that the 
combination of CDK9 and CDKI inhibition results in effective induction of 
apoptosis and may enhance the cytotoxic effect in cancer cells. 
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Appendix One 
Log2 values in the fold changes of the expression of the genes 
Accession log2 log2 Gene name 
Number CDKI-71 flavopiridol 
AB037730 -1.19 -1.46 kelch-like 13 (Drosophila) 
AB037732 -1.42 -0.91 RNA binding motif protein 27 
AB037780 -1.06 -1.15 mucin 20, cell surface associated 
AC004889 -1.09 -0.72 olfactory receptor, family 2, subfamily AO, 
member 1 pseudogene 
AC008737 -1.11 -0.50 C3 and PZP-like, alpha-2-macroglobulin domain 
containing 8 
AC008934 1.16 0.30 phosphodiesterase 4D, cAMP-specific 
(phosphodiesterase E3 dunce homolog, Drosophila) 
AC009970 -1.46 -0.84 hypothetical protein LOCI00286932 
ACOl2074 -1.26 -1.16 dystrobrevin, beta 
ACOl8988 -1.24 -0.97 adaptor-related protein complex 3, sigma 2 subunit 
AC021909 1.34 -0.07 neuregulin 1 
AC022215 1.30 -0.54 ribosomal protein L31 pseudogene 21 
AC024022 -1.06 -0.53 shisa homolog 3 (Xenopus laevis) 
AC079127 -1.10 -0.55 kinase suppressor of ras 2 
AE006639 -1.15 -0.61 mitogen-activated protein kinase 8 interacting 
protein 3 
AF114264 -1.20 -1.01 nexilin (F actin binding protein) 
AFl16627 -1.17 -0.77 GTP binding protein 2 
AL021155 1.16 0.29 SET binding factor I pseudogene 
AL031118 -1.01 -0.68 zinc finger protein 391 
AL031885 -1.16 -0.74 chloride channel, nucleotide-sensitive, I B 
AL078587 1.43 0.28 hypothetical LOC 1 00 134868 
AL162742 -1.14 -0.42 glutathione S-transferase omega 2 
AL353602 1.50 0.09 polymerase (DNA directed), eta 
AL353743 -1.19 -0.55 prohibitin pseudogene 
AL391839 ·1.07 -0.09 coiled-coil domain containing 7 
BC009350 -1.30 -0.58 eulcaryotic translation initiation factor 2 alpha 
kinase 4 
NM_000180 -1.16 -0.93 guanylate cyclase 2D, membrane (retina-specific) 
NM_000216 -1.04 -0.94 Ka\1mann syndrome 1 sequence 
NM_OOO261 -1.26 -0.67 myocilin, trabecular meshwork inducible 
glucocorticoid response 
NM_000478 -1.24 -1.12 alkaline phosphatase, liverlbonelkidney 
NM_OO0566 -1.01 -0.49 Fc fragment oflgG, high affinity Ic, receptor 
(CD64); Fc fragment oflgG, high affinity la, 
receptor (CD64) 
NM 000751 1.22 -0.06 cholinergic receptor, nicotinic, delta 
NM_000807 1.62 0.26 gamrna-aminobutyric acid (GABA) A receptor, 
alpha 2 
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NM 000831 -1.32 -0.81 glutamate receptor, ionotropic, kainate 3 
NM_000937 -1.63 -0.91 polymerase (RNA) 11 (DNA directed) polypeptide 
A,220kDa 
NM_000952 -1.15 -0.97 platelet-activating factor receptor 
NM_001416 -1.01 -0.44 similar to eukaryotic translation initiation factor 
4A; small nucleolar RNA, H/ACA box 67; 
eukaryotic translation initiation factor 4A, isoform 
I 
NM_001417 -1.04 -0.75 similar to eukaryotic translation initiation factor 
4H; eukaryotic translation initiation factor 4B 
NM_OO1634 1.70 0.36 adenosylmethionine decarboxylase I 
NM_OO2009 -1.35 -0.77 hypothetical LOCI00132771; fibroblast growth 
factor 7 (keratinocyte growth factor); fibroblast 
growth factor 7 pseudogene 2 
NM 002109 -1.57 -0.75 histidyl-tRNA synthetase 
NM 002110 -1.15 -0.47 hemopoietic cell kinase 
NM_002255 -1.04 -1.24 killer cell immunoglobulin-like receptor, two 
domains, long cytoplasmic tail, 4 
NM_0024 I 0 -1.41 -0.89 mannosyl (alpha-I ,6-)-glycoprotein beta-l,6-N-
acetyl-glucosaminyltransferase; hypothetical 
LOCI51162 
NM_002465 -1.36 -0.71 myosin binding protein C, slow type 
NM_OO2703 -1.45 -0.83 phosphorihosyl pyrophosphate amidotransferase 
NM_OO2769 -1.07 -0.86 protease, serine, 1 (trypsin 1); trypsinogen C 
NM_OO2926 -1.01 -0.02 regulator ofG-protein signaling 12 
NM_OO3222 -1.20 -1.02 transcription factor AP-2 gamma (activating 
enhancer binding protein 2 gamma) 
NM_003292 -1.33 -1.08 translocated promoter region (to activated MET 
oncogene) 
NM_OO3455 -1.21 -0.96 zinc finger protein 202 
NM_003520 -1.05 -1.10 histone cluster I, H2bn 
NM_OO3808 -1.02 -0.56 TNFSF 12-TNFSF 13 readthrough transcript; tumor 
necrosis factor (ligand) superfamily, member 12; 
tumor necrosis factor (ligand) superfamily, member 
13 
NM_003910 -1.09 -0.64 BUD31 homolog (S. cerevisiae) 
NM_004241 -1.01 -1.01 jumonji domain containing Ie 
NM_OO4390 -1.03 -0.16 cathepsin H 
NM_OO4436 -1.29 -1.45 endosulfine alpha 
NM_OO4513 -1.44 -0.65 interleukin 16 (lymphocyte chemoattractant factor) 
NM_004895 -1.17 -0.69 NLR family, pyrin domain containing 3 
NM_004963 -1.23 0.25 guanylate cyclase 2C (heat stable enterotoxin 
receptor) 
NM_004993 -1.10 -0.22 ataxin 3 
NM_OO5012 -1.26 -0.41 receptor tyrosine kinase-like orphan receptor I 
NM_OO5108 1.42 0.40 xylulokinase homolog (H. influenzae) 
NM_005319 -1.09 ·0.97 histone cluster 1, HI c 
NM_OO5321 ·1.04 -0.76 histone cluster 1, Hie 
NM_OO5322 ·1.22 ·0.76 histone cluster I, HI b 
NM_005488 -1.00 ·0.59 hypothetical LOCI00128526; target ofmybl 
(chicken) 
NM_OO5537 ·1.08 -0.61 inhibitor of growth family, member 1 
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NM 005626 -1.19 -0.94 splicing factor, arginine/serine-rich 4 
NM_005674 -J.lI -0.78 zinc finger protein 239 
NM_005807 -1.73 -1.59 proteoglycan 4 
NM_006273 -1.01 -0.78 chemokine (C-C motif) ligand 7 
NM 006608 -J.lO -1.06 putative homeodomain transcription factor I 
NM_006774 -1.00 -0.47 indolethylamine N-methyltransferase 
NM_OO72 I 2 -1.77 -1.29 ring finger protein 2 
NM_007237 -1.22 -1.35 SPI40 nuclear body protein 
NM 007280 -1.10 -0.66 Opa interacting protein 5 
NM_007320 -1.07 -0.62 RAN binding protein 3 
NM_007328 -1.55 -0.51 killer cell lectin-like receptor subfamily C, member 
I 
NM_012093 -1.07 -0.81 adenylate kinase 5 
NM_012352 -1.10 -0.60 olfactory receptor, family I, subfamily A, member 
2 
NM_012399 -1.05 -0.05 phosphatidylinositol transfer protein, beta 
NM_OI2446 -1.25 -0.77 single-stranded DNA binding protein 2 
NM_0\2485 -1.04 -0.84 hyaluronan-mediated motility receptor (RHAMM) 
NM_013960 -J.l9 -1.16 neuregulin I 
NM_OI3961 -1.00 -0.89 neuregulin I 
NM_013978 -1.09 -0.90 BCL2/adenovirus EI B 19kDa interacting protein 1 
NM_013980 -1.02 -0.86 BCL2/adenovirus E 1 B 19kDa interacting protein I 
NM_OI4138 -1.55 -1.42 family with sequence similarity 156, member A; 
family with sequence similarity 156, member B 
NM_014171 -1.20 -0.36 cysteine-rich PDZ-binding protein 
NM_014317 -1.29 -0.43 prenyl (decaprenyl) diphosphate synthase, subunit 1 
NM_014381 -1.09 -0.94 mutL homolog 3 (E. coli) 
NM_OI4412 -1.20 -1.16 similar to calcyclin binding protein; calcyclin 
binding protein 
NM_014580 -1.07 -0.92 solute carrier family 2 (facilitated glucose 
transporter), member 8 
NM_0\5442 1.40 0.20 CCR4-NOT transcription complex, subunit 1O 
NM_015485 -1.01 -1.23 RWD domain containing 3 
NM_016121 -1.23 -0.51 potassium channel tetramerisation domain 
containing 3 
NM_016299 -1.10 -0.73 heat shock 70kDa protein 14 
NM_016557 -1.11 -0.73 chemokine (C-C motif) receptor-like 1 
NM_016835 -1.46 -0.73 microtubule-associated protein tau 
NM_017493 -1.14 -0.73 OTU domain containing 4 
NM_017631 -1.08 -0.73 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 
NM_017853 1.25 0.85 thioredoxin-like 4B 
NM_OI79S3 -1.00 -1.16 zinc finger, HIT type 6 
NM_OI7972 -1.08 -0.60 chromosome 14 open reading frame 118 
NM_0\8012 -1.22 -1.30 kinesin family member 26B 
NM_OI8045 -1.10 -0.75 BSD domain containing I 
NM_018207 -1.20 -0.75 tripartite motif-containing 62 
NM_018281 -1.11 -0.66 enoyl Coenzyme A hydratase domain containing 2 
NM_018430 -1.01 -0.82 trans lin-associated factor X interacting protein I 
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NM_018590 -1.14 -0.38 chondroitin sulfate N-
acetylgalactosaminyltransferase 2; novel protein 
similar to chondroitin sulfate GaiN AcT -2 
(GALNACT -2) 
NM_018655 -1.54 -1.73 lens epithelial protein 
NM_018661 -1.00 -0.86 defensin, beta 103B; defensin, beta 103A 
NM_018714 -1.05 -0.57 component of oligomeric golgi complex I 
NM_018834 -1.32 -0.79 matrin 3 
NM_018839 -1.31 -0.57 NSFLl (p97) cofactor (p47) 
NM_018928 -1.07 -0.70 protocadherin gamma subfamily C, 3; 
protocadherin gamma subfamily C, 5; 
protocadherin gamma subfamily C, 4; 
protocadherin gamma subfamily A, 12 
NM_019119 -1.47 -1.08 protocadherin beta 10; protocadherin beta 9 
NM_020142 1.29 -0.90 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 4-like 2 
NM_020147 -1.34 -0.39 THAP domain containing 1O 
NM_020533 -1.26 0.11 mucolipin 1 
NM_020675 1.25 0.26 SPC25, NDC80 kinetochore complex component, 
homolog (S. cerevisiae) 
NM_020778 -1.31 -0.69 alpha-kinase 3 
NM_020779 -1.07 -0.56 WD repeat domain 35 
NM 020824 -1.20 -0.25 Rho GTPase activating protein 21 
NM_021035 -1.64 -1.02 zinc finger, NFXl-type containing I 
NM_021186 -1.45 -1.60 zona pellucida glycoprotein 4 
NM 022336 -1.71 -0.52 ectodysplasin A receptor 
NM 022576 -1.56 -1.22 phosducin 
NM_022781 -1.00 -0.93 ring finger protein 38 
NM_022830 -1.15 -0.79 terminal uridyly\ transferase I, U6 snRN A-specific 
NM_023013 -1.15 -1.04 PRAME family member 1 
NM_023038 -1.02 -0.52 ADAM metallopeptidase domain 19 (meltrin beta) 
NM_024071 -1.63 -0.71 zinc finger, FYVE domain containing 21 
NM 024164 -1.33 -0.82 tryptase alphalbeta I; tryptase beta 2 
NM_024292 -1.07 -0.92 ubiquitin-like 5 
NM_024694 -1.03 -0.79 chromosome 6 open reading frame 103 
NM_024743 -1.03 -1.00 UDP glucuronosyltransferase 2 family, polypeptide 
A3 
NM_024809 -1.09 -1.29 tectonic family member 2 
NM 024814 -1.16 -1.46 Cas-Br-M (murine) ecotropic retroviral 
transforming sequence-like 1 
NM_024908 -1.20 -0.27 WD repeat domain 76 
NM_024936 -1.04 -0.88 zinc finger, CCHC domain containing 4 
NM_025040 -1.31 -0.83 zinc finger protein 614 
NM 025081 -1.10 -0.75 KlAAI305 
NM_025170 -1.00 -0.93 phosphatidylinositoI-3,4,5-trisphosphate-dependent 
Rae exchange factor 2 
NM_025 194 -1.15 -0.19 inositol I A,5-trisphosphate 3-kinase C 
NM_032595 -1.36 0.05 protein phosphatase I, regulatory (inhibitor) subunit 
98 
NM_032946 -1.60 -1.12 nuclear RNA ellport factor 5 
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NM_033300 -1.05 -0.69 low density lipoprotein receptor-related protein 8, 
apolipoprotein e receptor 
NM_052937 1.04 0.63 protein-L-isoaspartate (D-aspartate) 0-
methyltransferase domain containing 1 
NM_053039 -1.16 -1.48 UDP glucuronosyltransferase 2 family, polypeptide 
B28 
NM 080588 1.25 0.56 protein tyrosine phosphatase, non-receptor type 7 
NM_145295 -1.07 -1.02 zinc finger protein 627 
NM 145911 -1.69 -1.33 zinc finger protein 23 (KOX 16) 
NM 173464 -1.10 -0.50 1(3)mbt-like 4 (Drosophila) 
NM_175055 -1.03 -1.07 histone cluster 3, H2bb 
NM_198568 -1.74 -0.95 gap junction protein, beta 7, 25kDa 
NM_199144 -1.47 -0.94 ubiquitin-conjugating enzyme E2 variant 1; 
ubiquitin-conjugating enzyme E2 variant 1 
pseudogene 2; transmembrane protein 189; 
TMEMI89-UBE2VI readthrough transcript 
X91l03 1.06 0.06 Hr44 antigen 
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Appendix Two 
Awards: 
• Janl20ll Nottingham University Endowed Postgraduate 
Prize 
• June/20l0 University of Nottingham Phannacy School BA 
Bull Postgraduate Award 
Conference presentations: 
• CDKI-71, a novel CDK9 inhibitor, is preferentially cytototoxic to 
cancer cells when compared with jlavopiridol 
Poster presentation: 21 st Meeting of the European Association for 
Cancer Research 
26-29 June 2010 Oslo, Norway 
• In vitro antitumor mechanism of a novel cyclin-dependent kinase 
inhibitor CDKI-83 
Poster presentation: NCR! 2010 
7-10 November 2010 Liverpool, UK 
• Pharmacokinetics, biodistribution, acute toxicity and in vivo anti-
tumour efficacy of paclitaxel solid dispersion 
Poster presentation: UK-PharmSci 2010 
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